

MAURO SCHECHTER

CURRICULUM VITAE

DADOS PESSOAIS

- **Filiação:** Marcos Schechter e Geny C. Schechter
- **Data de nascimento:** 16.12.1952
- **CRM.:** 52.28611.2
- **CPF:** 387044557/20



OCUPAÇÃO ATUAL

- **Professor Titular**, Disciplina de Infectologia, Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade Federal do Rio de Janeiro.
- **Investigador Principal**, Projeto Praça Onze, Universidade Federal do Rio de Janeiro.
- **Chefe**, Laboratório de Pesquisas, Serviço de Doenças Infecciosas e Parasitárias, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.
- **Professor Associado**, Department of International Health, School of Public Health, The Johns Hopkins University, Baltimore, Maryland, EUA.
- **Professor Associado**, Graduate School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA.
- **Pesquisador nível 1A**, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
- **Membro do Painel de Consenso sobre terapia anti-retroviral**, Organização Mundial da Saúde.
- **Membro do Painel de Consenso sobre terapia anti-retroviral**, International AIDS Society-USA, EUA.
- **Vice-Presidente**, The International Center for Equal Healthcare Access (ICEHA), EUA.
- **Membro, Comitê de Treinamento**, the Johns Hopkins University Fogarty AIDS International Training and Research Program, EUA.
- **Editor**, seção de Epidemiologia, AIDS Research and Human Retroviruses
- **Membro**, Comitê de Revisão Científica, European and Developing Countries Clinical Trials Partnership (EDCTP)
- **Membro do Comitê Científico**, South African AIDS Vaccine Initiative, South African Medical Research Council, Cidade do Cabo, África do Sul.
- **Membro do Comitê Científico**, European AIDS Treatment Network (NEAT), Comunidade Européia.
- **Membro do Conselho Editorial**, Future HIV Therapy, Londres, Inglaterra

- **Membro do Comitê Executivo**, AIDS Clinical Trials Group (ACTG), National Institutes of Health (NIH), EUA.

ESCOLARIDADE

- **Doutoramento**: Department of Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine, Inglaterra. Tese defendida em outubro de 1985, intitulada "*Studies on defined antigens of Trypanosoma cruzi*".
- **Mestrado**: Department of Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine, Inglaterra. Tese defendida em setembro de 1981, intitulada "*Antigen and Antibody Detection by the ELISA Test in Trypanosoma cruzi infections*".
- **Especialização**: Doenças Infecciosas e Parasitárias, Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, 1978-1979.
- **Residência Médica**: Serviço de Doenças Infecciosas e Parasitárias, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, 1978-1979.
- **Curso Superior**: Faculdade de Medicina, Universidade Federal do Rio de Janeiro, 1971-1977.

ATIVIDADES PROFISSIONAIS

- 2000- **Adjunct Professor**, Graduate School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA.
- 1996- **Professor Titular**, Disciplina de Infectologia, Departamento de Medicina Preventiva, Serviço de Doenças Infecciosas e Parasitárias, Universidade Federal do Rio de Janeiro.
- 1995- **Professor Associado**, Department of International Health, School of Public Health, Johns Hopkins University, Baltimore, Maryland, EUA.
- 1990- **Chefe**, do Laboratório de Pesquisas, Serviço de Doenças Infecciosas e Parasitárias, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.
- 1992-1996 **Professor Adjunto**, Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade Federal do Rio de Janeiro.
- 1989-1992 **Professor Visitante**, Departamento de Medicina Preventiva, Faculdade de Medicina, Universidade Federal do Rio de Janeiro.
- 1988-1989 **Research Assistant Professor**, Division of Immunology and Infectious diseases, Department of Medicine, New York University School of Medicine, New York, NY, EUA.
- 1986-1988 **Research Associate**, Laboratory of Molecular Parasitology, The Rockefeller University, New York, NY, EUA.
- 1981-1985 **Doutorando**, Department of Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine, Inglaterra.

- 1980-1981 **Mestrando**, Department of Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine, Inglaterra.
- 1978-1979 **Médico Residente**, Serviço de Doenças Infecciosas e Parasitárias, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.

BOLSAS DE ESTUDO NO BRASIL

- **CNPq** - Bolsa para curso de mestrado em Doenças Infecciosas e Parasitárias na Universidade Federal do Rio de Janeiro, 1980.
- **CNPq** - Pesquisador, 1989 -

BOLSAS DE ESTUDO NO EXTERIOR

- **CNPq** - Bolsa para curso de Doutorado em Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine, Inglaterra, 1981-1985.
- **ORS Awards Scheme**, Committee of Vice-Chancellors and Principals of the Universities of the United Kingdom - Bolsa para curso de Doutorado em Clinical Tropical Medicine, London School of Hygiene and Tropical, Inglaterra, 1981-1985.
- **British Council** - Bolsa para curso de Mestrado em Clinical Tropical Medicine, London School of Hygiene and Tropical Medicine, Inglaterra, 1980-1981.

TESES DEFENDIDAS

- **Schechter, M.** Antigen and antibody detection by the ELISA Test in *Trypanosoma cruzi* infections. M.Sc. Thesis 1981; University of London, UK.
- **Schechter, M.** Studies on defined antigens of *Trypanosoma cruzi*. Ph.D. Thesis 1985; University of London, UK.

PUBLICAÇÕES

1. **Schechter, M.**; Flint, JE; Voller, A; Guhl, F; Marinkelle, CJ; Miles, MA. Purified *Trypanosoma cruzi* glycoprotein for discriminative serological diagnosis of South American Trypanosomiasis (Chagas' Disease). The Lancet 1984; ii: 939-941
2. Flint, JE; **Schechter, M.**; Chapman, MD; Miles, MA. Zymodeme and species specificities of monoclonal antibodies raised against *T. cruzi*. Trans R Soc Hyg Trop Med 1984; 78: 193-202.
3. **Schechter, M.**; Luquetti, AO; Rezende, JM; Rassi, A, Miles, MA. Further evaluation of a lectin affinity purified glycoprotein (GP90) in the Enzyme Linked Immunosorbent Assay (ELISA) for the diagnosis of *T. cruzi* infection. Trans R Soc Hyg Trop Med 1985; 79: 637-640.
4. **Schechter, M.**; Stevens, AF; Allen, AK; Miles, MA. Investigations on the expression of a 72,000 molecular weight surface glycoprotein (GP72) in *T. cruzi* zymodemes and

- detection of anti-GP72 antibodies in Chagasic patients. *Trans R Soc Hyg Trop Med* 1985; 79: 131.
5. **Schechter, M**; Stevens, AF; Luquetti, AO; Snary, D; Allen, AK; Miles, MA. Prevalence of antibodies to a 72 Kilodalton glycoprotein (GP72) in patients with Chagas' disease and further evidence for zymodeme associated expression of GP72 carbohydrate epitopes. *Infection and Immunity* 1986; 53(3): 547-552.
 6. Scharfstein, J; **Schechter, M**; Senna, M; Peralta, JM; Mendonca-Previato, L; Miles, MA. *Trypanosoma cruzi*: Characterization and isolation of a 57/51,000 mw surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes. *J Immunol* 1986; 137 (4): 1336-1341.
 7. **Schechter, M**. Evaluation of a monoclonal antibody affinity purified antigen for zymodeme specific serological diagnosis of *Trypanosoma cruzi* infection. *Mem Inst Oswaldo Cruz* 1987; 82(1): 81-85.
 8. **Schechter, M**; Nogueira, N. Variations induced by different methodologies in *Trypanosoma cruzi* surface antigen profiles. *Mol Biochem Parasitol* 1988; 29: 37-46.
 9. Puccioni, M; **Schechter, M**; Ramos-Filho, C; Freitas, MRG; Novis, SAP. Neuropatia periférica e infecção pelo vírus da imunodeficiência humana. *Rev Bras Neurol* 1990; 26(6): 170-172.
 10. **Schechter, M**; Pannain, VLN; Oliveira, AV. Papovavirus associated esophageal ulceration in a patient with AIDS. *AIDS* 1991; 5(2): 238.
 11. Pinho, AMF; Marangoni, DV; Moreira, BM; Rodrigues, KM; Paz, NA; Ramos-Filho, CF; **Schechter, M**. Bacteriuria in patients with CDC group IV manifestations : A prospective study. *AIDS* 1991; 5(3): 342.
 12. Andrade, VL; Avelleira, JC; Marques, A; Vianna, FR; **Schechter, M**. Leprosy as a cause of false positive results in serological assays for the detection of antibodies to HIV-1. *Int. J Leprosy* 1991; 59 (1): 125-126.
 13. Puccioni, M; Correa, RB; Perez, MA; **Schechter, M**; Ramos-Filho, C; Novis, SAP. Complicações neurológicas na síndrome de imunodeficiência adquirida. *Arq Neuro-Psiquiatria* 1991; 49 (2): 159-163.
 14. Rodrigues, KMP; Puccioni-Sohler, M; Castineiras, TMPP; Papi JA; **Schechter, M**; Avila, C; Duarte, F; Novis, SAP. Miopatia e AIDS: Relato de um caso e revisão de literatura. *Arq de Neuropsiquiatria* 1991; 49 (3): 352-356.
 15. **Schechter, M**; Teixeira, MLB; Carvalho, ACC; Peres, M. Pulmonary tuberculosis in sputum-negative Brazilian AIDS patients. *Chest* 1992; 101 (4):1184.
 16. Pasternak, J; Baldy, JLS; **Schechter, M** Avaliação comparativa de eficácia e segurança de cefadroxil e cefalexina no tratamento de pneumonia bacteriana de origem comunitária em adultos. *Arq Bras Med* 1992; 66 (5).
 17. Vaisman, M; Monteiro, CB; Feijo, P; **Schechter, M**; Tendrich, M. Associação de Diabetes Insipidus central e AIDS. *Arq Bras Endocrinol Metabol.* 1992; 36 (2): 60-61.
 18. Cavalcanti, M; Ferreira-Jr, O; Puccioni, M; Novis, SAP; **Schechter, M**. HTLV I associated neurological manifestations in 4 generations of a Brazilian family. *J Acq Immun Def Synd* 1993; 6 (2): 213-217.

19. Lima, LAA; May, SB; Perez, MA; **Schechter, M.** Survival of HIV-infected Brazilian individuals: a model based on the World Health Organization staging system. *AIDS* 1993; 7:295-296.
20. Zajdenverg, R; Valle, SOR; Silva, RFF; Baptista, AA; **Schechter, M.** PPD reactivity and risk of development of tuberculosis in HIV infected brazilian patients. *Chest* 1993; 104 (2): 646.
21. Collareda, NL; Frota, AC; Silva-Oliveira, RH; **Schechter, M.** Breast-feeding and vertical transmission of HIV-1 in Rio de Janeiro, Brazil. *Pediatric AIDS and HIV Infection* 1993; 4 (4):195-197.
22. Durovni, B; Pinto, M; **Schechter, M.** AIDS case definitions in developing countries. *Lancet* 1993; 342 (ii): 1054.
23. Pinto, ME; Carvalho, AP; Nogueira, C; Ferreira-Jr O, **Schechter, M.** Prevalence of antibodies to Hepatitis C virus in populations at low and high risk for Sexually transmitted diseases in Rio de Janeiro, Brasil. *Mem Inst Oswaldo Cruz* 1993; 88(2): 305-307.
24. **Schechter, M;** Harrison, LH; Halsey, NA; Trade, G; Santino, M; Moulton, LH; Quinn, TC. Co-infection with Human T-Cell Lymphotropic Virus Type I and HIV in Brazil: Impact on CD4 Lymphocyte counts and Clinical Stage. *JAMA* 1994; 271:353-357.
25. **Schechter, M;** Zajdenverg, R; Machado, LL; Pinto, ME; Lima, LAAL; Perez, MA. Predicting CD4 counts in HIV-infected Brazilian individuals: a model based on the World Health Organization staging system. *J Acq Immun Def Synd* 1994; 7:163-168.
26. Pinho, AMF; Lopes, GS; Ramos-Filho, CF; Santos, OR; Oliveira, MPB; Halpern, M; **Schechter, M.** Urinary tract infection in men with AIDS. *GenitoUrin Med* 1994; 70:30-34.
27. Hofer, CB; Pinto, ME; Zajdenverg, R; **Schechter, M.** P24 antigenemia in HIV-1 infected Brazilian individuals correlates with other markers of disease progression. *J Infection* 1994; 29:129-131.
28. Nucci, M; **Schechter, M;** Spector, N; Pulcheri, W; Caiuby, MJ; Morais, JC; Maceira J; Carvalho, DM; Oliveira, HP. Antibiotic regimen as an independent risk factor for disseminated fungal infections in neutropenic patients. *Trans R Soc Hyg Trop Med* 1995. 89: 107-110.
29. Costa, SM; Shindo, N; Vicente, ANP; Pinto, ME; **Schechter, M;** Tanuri, A. Full sequence of GP120 of an HIV-1 variant (GWGR) highly prevalent in Brazil. *AIDS Res Hum Retrovirus* 1995. 11(9):1143-1145.
30. Pieniasek, D; Janini, LM; Ramos, A; Tanuri, A; **Schechter, M;** Peralta, JM; Vicente, ACP; Pieniasek, NJ; Schochetman, G; Rayfield, M. HIV-1 patients harbor viruses belonging to different subtypes: implication for the evolution of the pandemic. *Emerging Infect Dis* 1995. 1 (3): 86-88.
31. Kritski, A; Dalcomo, M; del Bianco, R; Melo, FF; Pinto, WP; **Schechter, M;** Castelo, A. Associação de tuberculose e infecção pelo HIV no Brasil. *Bol Oficina Sanit Panam* 1995. 118(6): 542-555.

32. Nardelli, B; Gonzales, CJ; **Schechter, M**; Valentine, FT. CD4⁺ blood lymphocytes are rapidly killed *in vitro* by contact with autologous immunodeficiency virus-infected cells. Proc Natl Acad Sci USA 1995. 92: 7312-7316.
33. Pinto, ME; **Schechter, M**. V3 peptide binding pattern and HIV-1 transmission route in Rio de Janeiro. Mem Inst Oswaldo Cruz 1995; 90(6): 683-685.
34. Nogueira, CM; Cavalcanti, M; **Schechter, M**; Ferreira-Jr, OC. Human T-Lymphotropic Virus Type I and II in Healthy Blood Donors in Rio de Janeiro, Brazil. Vox Sag 1996;70:47-48.
35. Janini LM, Pieniazek D, Peralta JM, **Schechter M**; Tanuri A; Vicente ACP; Torre LD; Pieniazek NJ; Luo CC; Kalish ML; Schochetman G; Rayfield MA. Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. Virus Genes 1996;13:69-81.
36. Gavão-castro, B; Couto-fernandez, JC; Mello, MA; Linhares, MIC; Castello-Branco, LR; Bongertz, V; Ferreira, PCP; Morgado, M; Sabino, E; Tanuri, A.; Carvalheiro, J; Suttmoller, F; Simonetti, JP; **Schechter, M**; Demacedo, LFB; Ueda, M. A nationwide effort to systematically monitor HIV-1 diversity in Brazil: preliminary results. Mem Inst Oswaldo Cruz 1996. 91(3):335-338.
37. Harrison, LH; Vaz, B; Taveira, DM; Quinn, TC; Gibbs, CJ; Souza, SH; McArthur, JC; **Schechter, M**. Myelopathy Among Brazilians Coinfected with Human T-Cell Lymphotropic Virus Type I and HIV. Neurology 1997; 48:13-17.
38. Harrison, LH; Quinn, TC; **Schechter, M**. Human T-Cell Lymphotropic Virus Type I Does Not Increase HIV Viral Load *in Vivo*. J Infect Dis 1997; 175:438-440.
39. **Schechter, M**. The future of tropical medicine: a Brazilian perspective. Lancet 1997; **349** (suppl III);29-30
40. Harrison, LH; **Schechter, M**. Human T cell Lymphotropic Virus Type II and Human Immunodeficiency Virus Type I Disease Progression. J Infect Dis (letter). J Infect Dis 1997; 176: 308.
41. Harrison, LH; Quinn, TC; **Schechter, M**. Coinfection with Human T Lymphotropic Virus Type I and Human Immunodeficiency Virus (letter). J Infect Dis 1997; 176: 544-545.
42. Respass, RA; Butcher, A; Wang, H; Chaowanachan, T; Young, N; Shaffer, N; Mastro, TD; Biryahwaho, B; Downing, R; **Schechter, M**; pascu, R; Zekeng, L; Kaptue, L; Gurtler, L; Eberle, J; Ellenberger, D; Fridlund, C; Rayfield, M; Kwok, S. Detection of genetically diverse Human Immunodeficiency Virus Type I group M and O isolates by PCR. J Clin Microbiol 1997; 35(5):1284-1286.
43. **Schechter, M**; Moulton, LH; Harrison, LH. HIV Viral Load and CD4⁺ Lymphocyte Counts in Subjects Coinfected with HTLV-1 and HIV-1. J AIDS 1997; 15:308-311.
44. Harrison, LH; **Schechter, M**. Myelopathy among brazilians coinfecting with human T-cell lymphotropic virus type I and HIV (letter). Neurology 1997; 49:1191.
45. Janini, LM; Tanuri, A; **Schechter, M**; Peralta, JM; Vicente, ACP; Torre, ND; Pieniazek, NJ; Luo, CC; Ramos, A; Soriano, V; Schochetman, G; Rayfield, M; Pieniazek, D.

Horizontal and vertical transmission of HIV-1 dual infections caused by viruses of subtypes B and C. *J Infect Dis* 1998;177:227-231.

46. Harrison, LH; **Schechter, M**. Coinfection with HTLV-I and HIV: Increase in HTLV-I-related outcomes but not accelerated HIV disease progression? *AIDS Patient Care and STDs* 1998; 12:619-623.
47. Pinto, ME; Tanuri, A; **Schechter, M**. Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil. *J Acq Immun Def Synd* 1998; 19:310-312.
48. Zhang, X; Fitzpatrick, L; Campbell, TB; Badaro, R; **Schechter, M**; Melo, MF; Brites, C; Sampaio, DP; Schooley, RT. Comparison of the Prevalence of Antibodies to Human herpesvirus-8 (Kaposi's Sarcoma- Associated Herpesvirus) in Brazil and in the United States. *J Infect Dis* 1998;178(5):1488-1491.
49. Lopes, GS; Harrison, LH; Lawrence, LH; Lima, LAA; Pinho, AMF; Hofer, CB; **Schechter, M**. Gender and Survival after AIDS in Rio de Janeiro, Brazil. *J Acq Immun Def Synd* 1998; 19(4):403-407.
50. **Schechter, M**; Struchiner, CJ; Harrison, LH. Protease Inhibitors as Initial Therapy for Individuals with an Intermediate Risk of HIV Disease Progression: Is More Necessarily Better? *AIDS* 1999; 13:97-102.
51. Ramos, A; Tanuri, A; **Schechter, M**; Rayfield, MA; Hu, DJ; Cabral, MC; Bandea, CI; Baggs, J; Pieniazek, D. Dual and Recombinant Infections: An Integral Part of the HIV Epidemic in Brazil. *Emerging Infect Dis* 1999; 5(1): 65-74.
52. Harrison, LH; Lago, R; Friedman, RK; Rodrigues, J; Santos, EM; Moulton, LH; **Schechter, M**. Incident HIV Infection in A High-Risk, Homosexual Male Cohort in Rio de Janeiro, Brazil. *J Acq Immun Def Synd* 1999;21:408-412
53. Tanuri, A; Vicente, AC; Otsuki, K; Ramos, CA; Ferreira, OC Jr; **Schechter, M**; Janini, LM; Pieniazek, D; Rayfield, MA. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. *Antimicrob Agents Chemotherapy* 1999. 43(2):253-8.
54. **Schechter, M**; Harrison, LH. Therapy of early HIV infection: Time for the pendulum to swing back ? *AIDS Clinical Care* 1999. 11(10):79-86.
55. Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hammer, SM; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; **Schechter, M**; Schooley, RT; Thompson, MA; Vella, SV; Yeni, PG; Volberding, PA. Antiretroviral Therapy for HIV Infection: Updated Recommendations of the International AIDS Society-USA Panel. *JAMA* 2000. 283(3):381390
56. Gordin, FM; Chaisson, RE; Matts, JP; Miller, C; Valdespino, JL; Hafner, R; Garcia, L; Coberly, J; **Schechter, M**; Klukowitz, AJ; Barry, A; O'Brien, RJ. An international, randomized trial of Rifampin and Pyrazinamide versus Isoniazid for prevention of tuberculosis in HIV-infected persons. *JAMA* 2000. 283 (11): 1445-1450.

57. Santoro-Lopes, G; Harrison, LH; Tavares, MD; Xexéo, A; Santos, ACE; **Schechter, M.** HIV-Disease Progression and V3 serotypes in Brazil: Is B Different from B-Br?. *AIDS Res and Human Retrov* 2000. 16(10): 953-958.
58. Barroso, PF; **Schechter, M;** Gupta, P; Melo, FM; Vieira, M; Murta, F; Souza, Y; Harrison, LH. Effect of Antiretroviral Therapy on HIV Shedding in Semen. *Ann Int Med* 2000. 133:280-284.
59. **Schechter, M;** Lago, RF; Melo, MF; Moreira, RI; Faulhaber, JC; Batista, S; Harrison, LH. Identification of a High-Risk, Heterosexual Population for HIV Prevention Trials in Rio de Janeiro, Brazil. *J Acq Immun Def Synd* 2000. 24:175-7
60. Hofer, CB; Harrison, LH; Struchiner, CJ; Moreira, RI; Lago, RF; Melo, MF; **Schechter, M.** Acute Retrovirus Syndrome among Prospectively-Identified Homosexual Males with Incident HIV Infection in Brazil. *J Acq Immun Def Synd* 2000. 25(2):188-191.
61. Perisse, A; **Schechter, M;** Moreira, RI; Lago, RF; Santoro-Lopes, G; Harrison, LH. Willingness to Participate in HIV Vaccine Trials among Men Who Have Sex with Men in Rio de Janeiro, Brazil. *J AIDS* 2000;25:459-463.
62. Pinho, AMF; Santoro-Lopes, G; Harrison, LH; **Schechter, M.** Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. *AIDS* 2001;15:2129-2135.
63. Santoro-Lopes, G; Pinho, AMF; Harrison, LH; **Schechter, M.** Reduced Risk of Tuberculosis among Patients with Advanced HIV Infection Treated with HAART in a Brazilian Cohort. *Clin Infect Dis* 2002; 34:543-546.
64. Martin, DF; Sierra-Madero, J.; Walmsley, S.; Wolitz, R.A.; Macey, K.; Georgiou, P.; Robinson, C.A.; Stempien, M.J.; and the Valganciclovir Study Group. A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis. *N Engl J Med* 2002; 15: 119-1126.
65. Yeni, PG; Hammer, SM; Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; **Schechter, M;** Schooley, RT; Thompson, MA; Vella, Stefano; Volberding, PA. Antiretroviral Treatment for Adult HIV Infection in 2002 Updated Recommendations of the International AIDS Society-USA Panel. *JAMA*, 2002; 288:222-235.
66. Hammer, SGD; Havlir, D; Mofenson, L; Van Beek, I; Vella, S; Chebet, L; Dybul, M; Giaquinto, C; Katabira, E; Katlama, C; Kazatchkine, M; Malkin, JE; McIntyre, C; M'Boup, S; Mokhbat, J; Mukherjee, J; Phanupak, P; **Schechter, M;** Avila Vittoria, M. Scaling up Antiretroviral Therapy in Resource-Limited Settings: *Guidelines for a public health approach*. World Health Organization, 2002.
67. **Schechter, M.** HIV vaccine evaluation center in Rio de Janeiro, Brazil. *Vaccine* 2002. 6;20(15):1909-11.
68. Barroso, PF; **Schechter, M;** Gupta, P; Bressan, C; Bonfim, A; Harrison, LH. Adherence to Antiretroviral Therapy and Persistence of HIV RNA in Semen. *Journal of Acquired Immune Deficiency Syndromes* 2003; 32:435-440.
69. A Safety Study of Oral Valganciclovir Maintenance Treatment of Cytomegalovirus Retinitis. Roche Valganciclovir Study Group. *Journal of Acquired Immune Deficiency Syndromes*, 2002; 30:392-400.

70. Hammer, SGD; Havlir, D; Klement, E; Scano, F; Malkin, JE; Delfraissy, JF; Lange, J; Mofenson, L; Harrington, M; **Schechter, M**; Kumarasamy, N; Duirier, N; Sow, PS; Banoo, S; Macharia, T. Scaling up Antiretroviral Therapy in Resource-Limited Settings: Guidelines for a public health approach, 2003 revision. World Health Organization, 2003 (http://www.who.int/3by5/publications/documents/arv_guidelines/en/).
71. Cook RL, May S, Harrison LH, Moreira RI, Ness RB, Batista S, Bastos M, **Schechter M**. High prevalence of sexually transmitted diseases in young women seeking HIV testing in Rio de Janeiro, Brazil. *Sex Transm Dis* 2004;31:67-72.
72. **Schechter, M**; Lago, RF; Mendelsohn, AB; Moreira, RI; Moulton, LH; Harrison, LH. Behavioral Impact, Acceptability, and HIV Incidence Among Homosexual Men With Access to Post-Exposure Chemoprophylaxis for HIV. *Journal of Acquired Immune Deficiency Syndromes* 2004;35:519-525.
73. Hofer, CB; **Schechter, M**; Harrison, LH. Effectiveness of Antiretroviral Therapy among Patients Who Attend Public HIV Clinics in Rio de Janeiro, Brazil. *Journal of Acquired Immune Deficiency Syndromes* 2004; 36:967-971.
74. Barroso, PF; Harrison, LH; Melo, MF; Batista, S; Bastos M; Faulhaber J; Moreira RI; Lago RF; **Schechter M**. Identification of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil, using a sensitive/less sensitive assay: An Update. *Journal of Acquired Immune Deficiency Syndromes* 2004;36:880-881.
75. Vibhagool, A; Cahn, P; **Schechter, M**; Smaill, F; Soto-Ramirez, L; Carosi, G; Montroni, M; Pharo, CE; Jordan, JC; Thomas, NE; Pearce, G. Triple Nucleoside Treatment with Abacavir Plus the Lamivudine/Zidovudine Combination Tablet (COM) Compared to Indinavir/COM in Antiretroviral Therapy-naïve Adults: Results of a 48-Week Open-label, Equivalence Trial. *Current Medical Research and Opinion* 2004;20: 1103-114.
76. Cahn, P; Vibhagool, A; **Schechter, M**; Soto-Ramirez, L; Carosi, G; Smaill, F; Jordan, JV; Pharo, CE; Thomas, NE; Steel, HM. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. *Current Medical Research and Opinion* 2004;20:1115–1123.
77. Yeni, PG; Hammer, SM; Hirsch, MS; Saag, MS; **Schechter, M**; Carpenter, CCJ; Fischl, MA; Gatell, JM; Gazzard, BG; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. *JAMA* 2004;291:251-265.
78. **Schechter M**. Therapy of early HIV infection: How far back should the pendulum swing? *J Infect Dis* 2004;190:1043-5.
79. Leth, FV; Phanuphak, P; Stoes, E; Gazzard, B; Cahn, P; Wood, R; Bloch, M; Katlama, C; Kastelein, JJP; **Schechter, M**; Murphy, R; Horban, A; Hall, D; Raffi, F; Lange, JMA; Reiss, P. Nevirapine and efavirenz elicit different changes in lipids and lipoproteins in antiretroviral therapy naive HIV-1 infected patients. *PloS Med* 2004; 1(1)e19: 64-74.
80. Coplan, PM; Gupta, SB; Dubey, AS; Pitisuttithum, P; Nikas, A; Mbewe, B; Vardas, E; **Schechter, M**; Kallas, EG; Freed, DC; Fu, TM; Mast, CT; Puthavathana, P; Kublin, J; Collins, KB; Chisi, J; Pendame, R; Thaler, SJ; Gray, G; McIntyre, J; Straus, WL; Condra, JH; Mehrotra, DV; Guess, HÁ; Emini, EA; Shiver, JW. Cross-Reactivity of Anti-HIV-1

- T-Cell Immune Responses Among the Major HIV-1 Clades in HIV-positive Individuals from Four Continents. *J Infect Dis* 2005;191:1427-1434
81. Egger, M; Boulle, A; **Schechter, M**; Miotti P. Antiretroviral therapy in resource-poor settings: Scaling up inequalities? *Int J Epidemiol* 2005:509-512.
 82. François Dabis, Eric Balestre, Paula Braitstein, Paolo Miotti, W.G. Martin Brinkhof, Martin Schneider, **Mauro Schechter**, Christian Laurent, Andrew Boulle, Charles Kabugo, Gorana Capkun, Catherine Seyler, James McIntyre, Eduardo Sprinz, David Bangsberg, Stefan Van der Borgh, Matthias Egger.. Cohort Profile: The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration. *Int J Epid* 2005; 34:979-986.
 83. Tuboi, SH; Harrison, LH; Sprinz, E; Albernaz, RKM, **Schechter, M**. Predictors of Virological Failure in HIV-1 Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil. *Journal of Acquired Immune Deficiency Syndromes* 2005;40:324-328.
 84. Braitstein, P; Brinkhof, MWG; Dabis, F; **Schechter, M**; Boulle, A; Miotti, P; Wood, R; Laurent, C; Sprinz, E; Seyler, C; Bangsberg, D; Balestre, E; Sterne, J; May, M; Egger, M. Mortality of HIV-1-infected patients during the first year of potent antiretroviral therapy: Comparative analysis of databases from low and high-income countries. *Lancet* 2006; 367: 817-24.
 85. Vettore, MV; **Schechter, M**; Melo, MF; Boechat, LJ; Barroso, PF. Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. *J infection* 2006;52:290-293.
 86. **Schechter, M**; Zajdenverg, R; Falco, G; Barnes, GL; Coberly, J; Moore, RD; Chaisson, RE. Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts. *Am J Respir Crit Care Med.* 2006; 173: 922-926.
 87. Vergara, TRC; Estrela, RCE; Suarez-Kurtz, G; **Schechter, M**; Cerbino-Neto, J; Barroso, PF. Poor Penetration of Lopinavir in the Male Genital Tract of Men Infected with HIV-1 in Brazil. *Ther Drug Monit* 2006;28:175-179.
 88. Gupta, SB; Mast, CT; Wolfe, ND; Novitsky, V; Dubey, SA; Kallas, EG; **Schechter, M**; Mbewe, B; Vardas, E; Pitisuttithum, P; Burke, D; Freed, D; Mogg, R; Coplan, PM; Condra, JH; Long, RS; Anderson, K; Casimiro, DR; Shiver, JW; Straus, WL. Cross-Clade Reactivity of HIV-1-Specific T-Cell Responses in HIV-1-Infected Individuals From Botswana and Cameroon. *J Acquir Immune Defic Syndr* 2006, 42(2):135-139.
 89. **Schechter, M**; Kallas, EG. HIV/AIDS Research in Brazil: The missing piece? *Future Virology*, 2006;1(4): 409-413.
 90. Hammer, SM; Saag, MS; **Schechter, M**; Montaner, JSG; Schooley, RT; Jacobsen, DM; Thompson, MA; Carpenter, CCJ; Fischl, MA; Gazzard, BG; Gatell, JM; Hirsch, MS; Katzenstein, DA; Richman, DD; Vella, S; Yeni, PG; Volberding, PA. Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel *JAMA* 2006;296:827-843.
 91. Hammer S; Riley A; Calmy A; Harries A; Duncombe C; Havlir D; Katabira E; Scano F; Malkin JE; Lange J; Mukerjee J; Currier J; Mofenson L; Harrington M; **Schechter M**; Kumarasamy N; Sow PS; Munderi P; Ojoo S; Cahn P; Pranuphak P, Eholie S; El Sadr W; Rodriguez W. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited setting: Towards universal access. WHO recommendations for a public

health approach.

92. **Schechter, M**; Tuboi, SH. Discordant immunologic and virologic responses to antiretroviral therapy. *J Antimicrob Chemoter* 2006; 58:506-510.
93. Grinsztejn B; Bastos FI; Veloso VG; Friedman RK; Pilotto JH; **Schechter M**; Derrico M; Andrade A; Lourenço MC; Moreira RI; Russomano F; Morgado M; Currier JS. Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. *Int J STD AIDS* 2006; 17: 473-478.
94. Yeni, P.; Cooper, D.A.; Aboulker, J.P.; Babiker, A.G.; Carey, D.; Darbyshire, J.H.; Florida, M.; Girard, P.M.; Goodall, L.; Hooker, M.H.; Mijch, A.; Meiffredy, V.; Salzberger, B.; Cooper, D.A.; Yeni, P.; Aboulker, J.P.; Antunes, F.; Babiker, A.; Becker, M.; Boukli, N.; BrunVezinet, F.; Carey, D.; Churchill, D.; Conway, B.; Chazallon, C.; Darbyshire, J.; DeWit, S.; Dusak, B.; Emery, S.; Flepp, M.; Gatell, J.; Girard, P.M.; Goodall, R.L.; Hemmer, R.; Hooker, M.; Law, M.; Loveday, C.; Lundgren, J.; Manion, D.; Meiffredy, V.; Mijch, A.; Mulcahy, F.; Orani, A.; Pharo, C.; Ristola, M.; Salzberger, B.; Sandstrom, E.; **Schechter, M.**; Schnittman, S. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. *Lancet* 2006;368:287-298.
95. Djomand, G; Duerr, A; Faulhaber, JC; Struchiner, CJ; Pacheco, AG; Barroso, PF; Melo, MF; **Schechter, M.** Clinical course of human immunodeficiency virus type 1 after seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil. *J Acquir Immune Defic Syndr*, 2006. 43:401-404.
96. Brinkhof, MWG; Egger, ME; **Schechter, M**; Dabis, F. Mortality of HIV infected patients in low income countries (letter). *Lancet* 2006;368:2207-2208.
97. May SB; Barroso PF; Nunes EP; Barcaui HS; Almeida MMT; Costa MD, Faulhaber JC; Santoro-Lopes G; **Schechter M.** Non-brand Name Drugs and Effectiveness of HAART in Brazil. *Braz J Med Biol Res*, 2007. 40:551-5.
98. Tuboi, SH; Brinkhof, MG; Egger, M; Stone, RA; Braitstein, P; Nash, D; Sprinz, E; Harrison, LH; **Schechter, M.** Discordant Responses to Potent Antiretroviral Treatment in Previously Naïve HIV-1 Infected Adults Initiating Treatment in Resource-Constrained Countries. *J Acquir Immune Defic Syndr* 2007;45:52-59.
99. **Schechter, M**; Nunes, EP. Monotherapy with Lopinavir/Ritonavir. *Expert Opin Investig Drugs* 2007; 16:735-741.
100. **Schechter, M.** Treatment at scale in Brazil: a physician's perspective. *AIDS* 2007, 21 (suppl 4):S31-S35.
101. McGowan, CC; Cahn, P; Gotuzzo, E; Padgett, D; Pape, JW; Wolff, M; **Schechter, M**; Masys, DR. Cohort Profile: Caribbean, Central and South America Network for HIV Research (CCASAnet) Collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Programme. *Int J Epid* 2007; doi: 10.1093/ije/dym073
102. Brinkhof, MWG; Egger, M; Boule, A; May, M; Hosseinipour, M; Braitstein, P; Dabis, F; Reiss, P; Bangsberg, D; Rickenbach, M; Meda, JMM; Mocroft, A; Keiser, O; Borgh, S; **Schechter, M.** Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. *CID* 2007; 45:1518-21.
103. Cleghorn, F; Pape, JW; **Schechter, M**; Bartholomew, C; Sanchez, J; Jack, N;

- Metch, BJ, Hansen, M; Allen, M; Cao, H; Tomaras, H; Gurunathan, S; Eastman, D; Ferro do Lago, R; Jean, S; Lama, J; Wright, PF. Lessons From a Multisite international trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120. *J Acq Imm Def Synd* 2007; 46:222-230.
104. Pacheco, AGF; Tuboi, SH; Faulhaber, JC; Harrison, LH; **Schechter, M**. Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. *PLOS One* 2008 3(1): e1531. doi:10.1371/journal.pone.0001531.
 105. Braitstein, P; Boulle, A; Egger, M; Brinkhof, MWG; Dabis, F; Laurent, C; **Schechter, M**; Tuboi, S; Sprinz, E; Miotti, P; Hosseinipour, M; Nash, D; May, M; Bangsberg, D; Low, N. Gender and the Use of Antiretroviral Treatment in Resource Constrained Settings: Findings from a Multicenter Collaboration. *J Women's Health* 2008; 17:47-55.
 106. Perno, CF; Moyle, G; Tsoukas, C; Ratanasuwan, W; Gatell, JM; **Schechter, M**. Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral drugs. *J Med Virol* 2008; 80:565-576.
 107. Keiser, O; Anastos, K; **Schechter, M**; Balestre, E; Myer, L; Boulle, A; Bangsberg, D; Touré, H; Braitstein, P; Sprinz, E; Nash, D; Hosseinipour, M; Dabis, F; May, M; Brinkhof, M; Egger, M. Antiretroviral therapy in resource-limited settings, 1996 to 2006: Patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. *Trop Med and Int Health* 2008; 13:1-10.
 108. Moyle, G; Gatell, J; Perno, CF; Ratanasuwan, W; **Schechter, M**; Tsoukas, C. Potential for New Antiretrovirals to Address Unmet Needs in the Management of HIV-1 Infection. *AIDS Patient Care and STDs* 2008;22:1-13.
 109. Brinkhof, MWG; Dabis, F; Myer, L; Bangsberg, DR; Boulle, A; Nash, D; **Schechter, M**; Laurent, C; Keiser, O; May, M; Sprinz, E; Egger, M; Anglaret, X. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. *Bull WHO* 2008;86:559-567.
 110. Steigbigel, RT; Cooper, DA; Kumar, PN; Eron, JE; **Schechter, M**; Markowitz, M; Loutfy, MR; Lennox, JL; Gatell, JM; Rockstroh, JK; Katlama, C; Yeni, P; Lazzarin, A; Clotet, B; Zhao, J; Chen, J; Ryan, DM; Rhodes, RR; Killar, JA; Gilde, LR; Strohmaier, KM; Meibohm, AR; Miller, MD; Hazuda, DJ; Nessly, ML; DiNubile, MJ; Isaacs, RD; Nguyen, BY; Teppler, H. Efficacy and safety of The HIV-integrase-inhibitor Raltegravir (MK-0518) combined with pttimized background therapy in treatment-experienced patients with unsuppressed multi-drug resistant HIV-1 infection: Primary results of the BENCHMRK 1 and 2 phase III trials. *New Eng J Med* 2008;359:339-354.
 111. Cooper, DA; Steigbigel, RT; Gatell, JM; Rockstroh, JK; Katlama, C; Yeni, P; Lazzarin, A; Clotet, B; Kumar, PN; Eron, JE; **Schechter, M**; Markowitz, M; Loutfy, MR; Lennox, JL; Zhao, J; Chen, J; Ryan, DM; Rhodes, RR; Killar, JA; Gilde, LR; Strohmaier, SM; Meibohm, AR; Miller, MD; Hazuda, DJ; Nessly, ML; DiNubile, MJ; Isaacs, RD; Teppler, H; Nguyen, BY. Efficacy of the HIV-integrase-inhibitor raltegravir (MK-0518) combined with optimized background therapy in treatment-experienced patients with unsuppressed multi-drug resistant HIV-1 infection: Subgroup and resistance analyses from the BENCHMRK 1 and 2 phase III trials. *New Eng J Med* 2008; 359: 355-365.
 112. Périssé, ARS; Langenberg, P; Hungerford, L; Boulay, M; Charurat, M;

- Schechter, M**; Blattner, W. The use of supplementary techniques to increase recall of sex partners in a network-based research study in Rio de Janeiro, Brazil. *Sex Transm Dis Sex Transm Dis*. 2008;35:674-678.
113. Pacheco, AGF; Saraceni, V; Tuboi, SH; Moulton, LH; Chaisson, RE; Cavalcante, SC; Durovni, B; Faulhaber, JC; Golub, JE; King, B; **Schechter, M**; Harrison, LH. Validation of a hierarchical deterministic record linkage algorithm: application on HIV-infected cohorts and mortality databases in Brazil. *Am J Epid* 2008 (Advance Access published online on October 9, 2008, doi:10.1093/aje/kwn249).
114. Nash, D; Katyal, M; Brinkhof, MWG; Keiser, O; May, M; Hughes, R; Dabis, F; Wood, R; Sprinz, E; **Schechter, M**; Egger, M. Long-term immunologic response to antiretroviral therapy in low income countries: A collaborative analysis of prospective studies (aceito para publicação).
115. Barroso, PF; Souza, MB; Lago, RF; Pedrosa, J; Yoshida, CB; Faulhaber, JC; Costa, MD; **Schechter, M**. Barriers to recruit female commercial sex workers for HIV vaccine trials: The Rio de Janeiro experience (aceito para publicação).
116. Périssé, ARS; Langenberg, P; Hungerford, L; Boulay, M; Charurat, M; **Schechter, M**; Blattner, W. Egocentric network data provides additional information for characterizing an individual's HIV risk profile (submetido).
117. Katlama, C; Haubrich, R; Lalezari, J; Lazzarin, A; Madruga, JV; Molina, JM; **Schechter, M**; Peeters, M; Vingerhoets, J; Woodfall, B; De Smedt, G. Efficacy and safety of Etravirine (ETR; TMC125) over 48 weeks in treatment-experienced HIV-1 infected patients: pooled analysis of DUET-1 and -2 (submetido).
118. Almeida, MMTB; Tuboi, SH; Barroso, PF; Batista, SM; Teles, S; Grangeiro, JR; Melo, MF; Zajdenverg, R; Lago, RF; **Schechter, M**. Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil (submetido).
119. Pacheco, AGF; Tuboi, SH; May, SB; Moreira, LFS; Ramadas, L; Nunes, EP; Merçon, M; Faulhaber, JC; Harrison, LH; **Schechter, M**. Temporal changes in causes of death among HIV-infected patients in the HAART era in Brazil (submetido).
120. Périssé, ARS; **Schechter, M**; Blattner, W. Association between male circumcision and prevalent HIV infections in Rio de Janeiro, Brazil (submetido).

EDITORACÃO DE LIVROS

121. Doenças Infecciosas: Conduta diagnóstica e terapêutica. **Schechter, M** & Marangoni, DV, editores. Editora Guanabara Koogan, Rio de Janeiro, 1994.
122. Manual de HIV/AIDS. Rachid, M & **Schechter, M**. Editora Revinter, Rio de Janeiro, 1996.
123. Manual de HIV/AIDS. Rachid, M & **Schechter, M**. Editora Revinter, Segunda Edição, Rio de Janeiro, 1997.
124. Manual de HIV/AIDS. Rachid, M & **Schechter, M**. Editora Revinter, Terceira Edição, Rio de Janeiro, 1998.
125. Doenças Infecciosas: Conduta diagnóstica e terapêutica. **Schechter, M** & Marangoni, DV, editores. Editora Guanabara Koogan, Rio de Janeiro, Segunda Edição, 1998.

126. Manual de HIV/AIDS. Rachid, M & **Schechter, M.** Editora Revinter, Quarta Edição, Rio de Janeiro, 1999.
127. Manual de HIV/AIDS. Rachid, M & **Schechter, M.** Editora Revinter, Quinta Edição, Rio de Janeiro, 2000.
128. Manual de HIV/AIDS. Rachid, M & **Schechter, M.** Editora Revinter, Sexta Edição, Rio de Janeiro, 2001.
129. Manual de HIV/AIDS. Rachid, M & **Schechter, M.** Editora Revinter, Sétima Edição, Rio de Janeiro, 2002.
130. Manual de HIV/AIDS. Rachid, M & **Schechter, M.** Editora Revinter, Oitava Edição, Rio de Janeiro, 2004.
131. Manual de HIV/AIDS. Rachid, M & **Schechter, M.** Editora Revinter, Nona Edição, Rio de Janeiro, 2007.
- 132.

CAPÍTULOS DE LIVRO NO BRASIL

133. **Schechter, M.** Diabetes e infecção. *In* Diabetes Mellitus na prática médica. Vaisman, M & Tendrich M, Editores. Editora Cultura Médica, Rio de Janeiro, 1994; 231-237.
134. **Schechter, M.** Diabetes Mellitus e Doenças Infecciosas. *In* Diabetes Mellitus – Clínica, Diagnóstico e Tratamento Multidisciplinar. Oliveira, P.E & Milech, A, Editores. Editora Atheneu, São Paulo, 2004; 199-215.

CAPÍTULOS DE LIVRO NO EXTERIOR

135. **Schechter, M.**; Charles, M. Univesal Access to Antiretroviral Therapy: The Brazilian Experience. *In* Global HIV/AIDS Medicine. Editora Saunders-Elsevier, USA; 2008. 695-702.
136. **Schechter, M.**; Wood, R. Approach to the Management of HIV/AIDS in Developing Countries. *In* Sexually Transmitted Diseases, Fourth Edition. McGraw- Hill Medical. USA, 2008; 1977-1992.
137. Galvão, J.; Teixeira, P.B.; Vitória, M.; **Schechter, M.** How the Pandemic Shapes the Public Health Response – the Case of HIV/AIDS in Brazil. *In* Public Health Aspects of HIV/AIDS in Low and Middle Income Countries. Oxford University Press, USA, 2008; 135-150
138. **Schechter, M.**; Tuboi, S. Cohort studies in Brazil: Projeto Praça Onze. *In* A Decade of HAART The Development and Global Impact of Highly Active Antiretroviral Therapy. Springer, EUA, 2008; 311-328.

PUBLICAÇÕES EM REVISTAS DE DIVULGAÇÃO CIENTÍFICA

139. Ministério da Saúde. Revisão da definição nacional do caso de AIDS em adultos. Boletim do Ministério da Saúde, Programa Nacional de Doenças sexualmente transmissíveis/AIDS 1992.
140. **Schechter, M.** AIDS. *Ars Curandi* 1993; 6: 20-32.
141. **Schechter, M.** O que há de novo em vacinas contra a AIDS. *Vitrô* 1993; 1(2): 8-11.

142. Durovni, B; Pinto, M; **Schechter, M.** Avaliação da performance de 5 definições de casos de AIDS. AIDS, Boletim Epidemiológico. Ministério da Saúde, Programa Nacional de Doenças sexualmente transmissíveis/AIDS 1993; VI(11): 2-4.
143. **Schechter, M.** Perspectivas para o desenvolvimento de vacinas contra a AIDS. Ciência Hoje 1994; 17(101): 54-57.
144. **Schechter, M.** AIDS: As vacinas. Ciência Hoje das Crianças 1995; 8(48): 4-5.
145. **Schechter, M.** Coinfecção por HIV e HTLV-1. Ars Curandi 1995; 9 (28): 33-36.
146. Costa, MM; Walker, APG; **Schechter, M.** Doenças infecto-contagiosas e amamentação. Feminina 2000; 28(4): 187-190.
147. **Schechter, M.** HIV Treatment and Care in Resource-Limited Settings. Medscape 2003 (<http://www.medscape.com/viewarticle/459943>).
148. **Schechter, M.** Scaling Up Antiretroviral Therapy for Developing Countries - We Can Walk and Chew Gum at the Same Time. Medscape 2003 (<http://www.medscape.com/viewarticle/458759>).
149. Rachid, M; **Schechter, M.** Medicamentos anti-retrovirais e drogas recreativas: Interações medicamentosas. Prática Hospitalar 2004;VI(34):98-100.

PARTICIPAÇÕES EM CONGRESSOS INTERNACIONAIS

150. Chapman, M.D.; Snary, D.; Flint, J.E.; **Schechter, M.**; Miles, M.A. (1983). Monoclonal antibodies which define a 72K glycoprotein and tissue cross reacting antigens in *T. cruzi*. Fifth International Congress of Immunology, Kyoto, Japan.
151. **Schechter, M.**; Flint, J.E.; Miels, M.A. (1984). Prospects for species and strain specific diagnosis of *T. cruzi* infection. XI International Congress for Tropical Medicine and Malaria, Calgary, Canada.
152. Stevens, A.F.; **Schechter, M.**; Chapman, M.D.; Allen, A.K.; Miles, M.A. (1985). Quantitation of 72,000 molecular weight cell surface glycoprotein in *Trypanosoma cruzi* zymodemes and detection of anti-GP72 antibodies in patients carrying different zymodemes. Joint meeting between The British Society of Immunology and The British Society for Allergy and Clinical Immunology, London, UK.
153. **Schechter, M.** ; Valentine, F.T. (1989). Differences in killing of CD4 cells induced by HIV isolates from asymptomatic and AIDS patients, as measured by Cr51 release assay. V International Conference on AIDS, Montreal, Canada.
154. **Schechter, M.**; May, S.B.; Bretas, G.; Ramos-Filho, C.F.; Lima, L.A.A. (1990). A pre-evaluation of a new, WHO- sponsored staging system for HIV infection. VI International Conference on AIDS, San Francisco, USA.
155. Peixoto, M.A.C.; Caiuby, M.J.; Assis, T.L.; **Schechter, M.** (1990). A higher than expected frequency of Histoplasmosis : Importance of routine obtention of blood cultures for fungi. VI International Conference on AIDS, San Francisco, USA.
156. Felix de Pinho, A.M.; Marangoni, D.V.; Moreira, M.B.; Ramos-Filho, C.F.; Rodriguez, K.M.P.; **Schechter, M.**; Paz, N.A. (1990). Possible high frequency of bacteriuria among brazilian AIDS patients. VI International Conference on AIDS, San Francisco, USA.

157. Sohler, M.P.; Correa, R.B.; Perez, M.A.; **Schechter, M.**; Ramos-Filho, C.F.; Novis, S.A.P. (1990). Criteria for presumptive diagnosis of neurotoxoplasmosis : Are they adequate? VI International Conference on AIDS, San Francisco, USA.
158. Sohler, M.P.; Correa, R.B.; Perez, M.A.; **Schechter, M.**; Ramos-Filho, C. F.; Novis, S.A.P. (1990). Comparative study of neurological complications in 172 cases of HIV infection. VI International Conference on AIDS, San Francisco, USA.
159. Manela-Azulay, M.; Caneschi, J.R.T.; Cavalcanti, M.; Ramos-Filho, C.F.; Perez, M.A.; **Schechter, M.**; Pereira Jr., A.C.(1990). Dermatological findings in patients with advanced HIV-related disease in Brazil. VI International Conference on AIDS, San Francisco, USA.
160. Ramos-Filho, CF; **Schechter, M.** (1990). Natural history of HIV infection in Brazil and other parts of the world: A proposal for a comparative study. VII INCLEN, Puebla, Mexico.
161. Cruz, MW; Sohler, MP; Correa, RB; Cavalcanti, M; **Schechter, M.**; Novis, SAP. (1991). VIII Congresso Pan-Americano de Neurologia, Montevideo, Uruguai.
162. Sohler, M.P.; Correa, R.B.; Cavalcanti, M.; **Schechter, M.**; Novis, S.A.P.(1991). Manifestations neurologiques associees a l'infection par l'HTLV-1 chez une famille bresilienne. Congres de Neurologie Tropicale, Limoges, Franca.
163. Correa, RB; Sohler, MP; Costa, MF; Zayen, E; Novis, SAP; **Schechter, M.** (1991). L'impact des manifestations neurologiques sur la survie des patients bresiliens atteints par le SIDA. Congres de Neurologie Tropicale, Limoges, Franca.
164. Cavalcanti, M.; **Schechter, M.**; Sohler, M.; Leite, D.M.; Ferreira-Junior, O.C. (1991). Vertical and horizontal transmission of HTLV-1 in 4 generations of a brazilian family. VII International Conference on AIDS, Florenca, Italia.
165. **Schechter, M.**; Teixeira, M.L.B.; Carvalho, A.C.C.; Peres, M. (1991). Predictors of pulmonary tuberculosis in sputum-negative brazilian AIDS patients. VII International Conference on AIDS, Florenca, Italia.
166. **Schechter, M.**; Sereno, A.B.; Espanha, C.; Cerqueira, E.M.F.P. (1991). Predictors of fungemia in AIDS patients: A case-control study. VII International Conference on AIDS, Florenca, Italia.
167. **Schechter, M.**; Leite, DM, Zajdenverg, R; Machado, LL; Ramos-Filho, CF; Perez, MA. (1992).Predictors of CD4 counts in HIV-infected Brazilian individuals. VIII International Conference on AIDS, Amsterdam, Holanda.
168. Lima, LAA; May, SB; Ramos-Filho, CF; Perez, M; **Schechter, M.** (1992). Survival of HIV-1 infected Brazilian individuals: a model based on the WHO staging system VIII International Conference on AIDS, Amsterdam, Holanda.
169. Pinho, A.M.F.; **Schechter, M.**; Oliveira, MPB; Halpern, M; Gouveia, CA; Ramos-Filho, CF. (1992). Urinary Tract Infection Is More Common In AIDS Patients Than In Asymptomatic HIV-infected Individuals, Or In Non-HIV Infected Patients. VIII International Conference on AIDS, Amsterdam, Holanda.
170. Zajdenverg, R; Machado, LM; Valle, SOR; Silva, DRFF; Souza, ACM; Baptista, AA; Perez, MA; **Schechter, M.** (1992). PPD Reactivity and Risk of Development of Tuberculosis in HIV Infected Brazilian Patients. VIII International Conference on AIDS, Amsterdam, Holanda.

171. Werneck, EB; Carvalho, ACC; Kritski, A; Cavalcanti, M; Santino MR; **Schechter, M.**; Qinn, T; Harrison, L; Halsey, N. (1992). Prevalence of Retroviral Infections in Intravenous Drug Users in Rio de Janeiro, Brazil. VIII International Conference on AIDS, Amsterdam, Holanda.
172. Werneck, EB; Silva, SGC; Rodrigues, CA; Kritski, AL; Ferreira, JA; **Schechter, M.**; Galvao-Castro, B. (1992). Measurement of false-positive rate in a screening program for HIV-1 among 1398 patients with tuberculosis in Rio de Janeiro, Brazil. VIII International Conference on AIDS, Amsterdam, Holanda.
173. Cheingsong-Popov, R; Garasy, H; Callow, D; Bobkov, A; Wasi, C; Potrascu, R; Kalsebu, F; Van de Perre, P; Gurtler, L; Gilks, C; Constantine, N; **Schechter, M.**; Beddows, S; Weber, J. (1992). Antigenic and genomic diversity of the HIV-1 V# loop: Analysis of geographical variation by serology , neutralization and sequencing. VIII International Conference on AIDS, Amsterdam, Holanda.
174. Lacerda, MCR; Cardoso, SW; Perez, MA; **Schechter, M.** (1992). Private versus state medical care of AIDS patients in Rio de Janeiro, Brasil: Impact on survival. VIII International Conference on AIDS, Amsterdam, Holanda.
175. Collareda, N; Oliveira, RS; **Schechter, M.** (1992). Parenteral behaviour and vertical transmission of HIV-1 in Rio de Janeiro, Brasil. VIII International Conference on AIDS, Amsterdam, Holanda.
176. Werneck, EB; Silva, SGC; Rodrigues, CA; Kritsky, A; Ferreira, JA; **Schechter, M.**; Galvao-Castro, B. (1992). Measurement of false positive rate in a screening program for HIV-1 among 1398 patients with tuberculosis in Rio de Janeiro, Brasil. VIII International Conference on AIDS, Amsterdam, Holanda.
177. Dines, I; **Schechter, M.**; Leite, DM; Pinto, ME; Persechini, PM. (1992). NK activity in HIV infected brazilian individuals with different degrees of immune disfunction. VIII International Conference on AIDS, Amsterdam, Holanda.
178. **Schechter, M.**; Leite, DM, Zajdenverg, R; Machado, LL; Ramos-Filho, CF; Perez, MA. (1992). Predictors of CD4 counts in HIV-infected Brazilian individuals: A model based on the WHO staging system. VII International Conference on AIDS in Africa, Yaounde, República de Camaroes.
179. Durovni, B, Pinto, M; **Schechter, M.** (1993). A prospective evaluation of 6 AIDS case definitions in Rio de Janeiro, Brazil. IX International Conference on AIDS, Berlin, Alemanha.
180. **Schechter, M.**; Trade, G; Pinto, ME; Dines, I; Quinn, TC; Halsey, NA; Harrison, LH. HIV-1 and HTLV-1 infection: A case-control study. IX International Conference on AIDS, Berlin, Alemanha.
181. Dines, I; **Schechter, M.**; Silva, AT; Persechini, PM. (1993) Clinical correlates of NK cell number and activity in HIV positive patients. IX International Conference on AIDS, Berlin, Alemanha.
182. May, SB; Perez, MA; Pinto, ME; **Schechter, M.**; Ramos-Filho, CF. (1993). High prevalence of HIV-1 infection in a representative sample of childbearing women in Rio de Janeiro, Brazil. IX International Conference on AIDS, Berlin, Alemanha.
183. Pinto, ME; Carvalho, AP; Nogueira, C; Ferreira-J, O; **Schechter M.** (1993). Prevalence of antibodies to Hepatitis C virus in populations at low and high risk for

- sexually transmitted diseases in Rio de Janeiro. IX International Conference on AIDS, Berlin, Alemanha.
184. Dines, I; **Schechter, M**; Silva, AT; Persechini, PM. (1993). Natural Killer cell function and number in HIV-1 positive patients: CD16/56⁺ with CD3⁻ or CD3⁺ phenotype. IX International Conference on AIDS, Berlin, Alemanha.
 185. Santos, MS; Guimaraes MDC; **Schechter, M**; Boschi-Pinto, C; Castilho, E; Neves Jr, I. (1993). Prevalence of HTLV infection among heterosexual couples with HIV positive male index cases. (1993). IX International Conference on AIDS, Berlin, Alemanha.
 186. **Schechter, M**; Pinto, ME; Hofer, CB; Zajdenverg, R. (1993). Correlates of p24 antigenemia in HIV-1 infected Brazilian individuals. IX International Conference on AIDS, Berlin, Alemanha.
 187. Pinto, ME; Cheingsong-Popov, R; Weber, J; **Schechter, M**. (1993). Correlates of reactivity to V3 loop peptides in HIV-1 infected patients in Rio de Janeiro, Brazil. IX International Conference on AIDS, Berlin, Alemanha.
 188. May, SB; Perez, MA; **Schechter, M**. (1993). HIV-1 prevalence in 4536 childbearing women attending maternity wards in Rio de Janeiro: A model based in correspondence analysis. IX International Conference on AIDS, Berlin, Alemanha.
 189. Harrison, LH; **Schechter, M**; Halsey, NA; Moulton, LH; Quinn, TC. (1993). Coinfection with Human T-cell Lymphotropic Virus Type I (HTLV-I) among adults with HIV infection in Brazil. V B. Frank Polk Symposium, Baltimore, EUA.
 190. Cruz, MW; Correa, RB; Sohler, MP; Vaz, BP; **Schechter, M**; Novis, SAP. (1993). ENMG and SSEP Study in HTLV-1 patients. XIII International Congress of Electroencephalography and Clinical Neurophysiology. Vancouver, Canada.
 191. **Schechter, M**; Trade, G; Pinto, ME; Dines, I; Quinn, TC; Halsey, NA; Harrison, LH. HIV-1 and HTLV-1 dual infection: Impact on CD4 counts and clinical stage. VII International conference on AIDS in Africa.
 192. Nucci, M; **Schechter, M**; Spector, N; Pulcheri, W; Caiuby, MJ; Morais, JC; Maceira J; Carvalho, DM; Oliveira, HP. (1993). Antibiotic regimen as an independent risk factor for disseminated fungal infections in neutropenic patients (Submetido). Trends in Invasive fungal infections II, Manchester, Inglaterra.
 193. Harrison, LH; **Schechter, M**; Halsey, NA; Moulton LH; Quinn, TC. (1993). Ompact of co-infection with HTLV-1 and HIV on markers of HIV disease progression. I National Conference on Human Retroviruses and related infections. Washington, EUA.
 194. Janini, LM; Luo, C-C; Peralta, JM; **Schechter, M**; Kalish, ML; Pieniazek, N; de La Torre, N; Schochetman, G; Rayfield, M; Pieniazek, D. (1994). Identification of three distinct HIV-1 subtypes in Brazil based on the protease gene. 93rd general meeting, American Society for Microbiology, Las Vegas, EUA.
 195. Harrison, LH; Vaz, B; McArthur, JC; **Schechter, M**. (1994). HTLV-1-related neurologic manifestations among Brazilians subjects co-infected with HTLV-1 and HIV. VIth International Conference on Human Retrovirology: HTLV, New Jersey, EUA.
 196. Murta F; **Schechter, M**; Zajdenverg, R; Artemenko, S; Gay, V. (1994). Reasons for participating in clinical trials in Brazil. X International Conference on AIDS, Yokohama, Japão.

197. Costa, SM; Shindo, N; Vicente, ANP; Pinto, ME; **Schechter, M**; Tanuri, A. (1994). Full sequence of GP120 of an HIV-1 variant (GWGR) highly prevalent in Brazil. X International Conference on AIDS, Yokohama, Japão.
198. Harrison, LH; **Schechter, M**; Vaz, BP; McArthur, JC. (1994). HIV-1/HTLV-1 coinfection is associated with a high frequency of myelopathies. X International Conference on AIDS, Yokohama, Japão.
199. **Schechter, M**; Oliveira, E,; Pinto, ME; Souza, VMA; Bronstein, M. (1994). Heat versus acid dissociation of immune complexes for the detection of p24 antigenemia. X International Conference on AIDS, Yokohama, Japão.
200. Nardelli, B; Gonzales, CJ; **Schechter, M**; Valentine, FT. (1994). HIV-infected cells can kill CD4+ cells upon contact. X International Conference on AIDS, Yokohama, Japão.
201. Kritski, AL; Carvalho, ACC; **Schechter, M**; Vieira, MAS; Oliveira, J; Werneck, EB; Ferreira, O; Novort, N; Hearst, N. (1994). HIV-1, HTLV-1 and tuberculosis among intravenous drug users in Rio de Janeiro, Brazil. X International Conference on AIDS, Yokohama, Japão.
202. Janini, M; Pieniazek, D.; Luo, C-C.; DeLatorre, N.; Peralta, J.M.; **Schechter, M**.; Tanuri, A.; Pieniazek, N.; Schochetman, G.; Rayfield, M. (1995). Fluctuations in culutre of distinct HIV-1 strains from dually infected persons. II National Conference on Human Retroviruses and Related Infections, Washington, USA.
203. Pieniazek, D.; Janini, M; ; Luo, C-C.; DeLatorre, N.; Peralta, J.M.; Tanuri, A.; **Schechter, M**.; Pieniazek, N.; Kalish, M.; Schochetman, G.; Rayfield, M. (1995). Confirmation of homotypic dual infections with HIV-1 and phylogenetic analyses of the contributing subtypes. II National Conference on Human Retroviruses and Related Infections, Washington, USA.
204. Harrison, L.H.; **Schechter, M**.; Vaz, B.; MD. JC. Mcarthur (1995). Myelopathy Among Brazilians Coinfected With Human T-Cell Lymphotropic Virus Type I and HIV. 35Th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA.
205. **Schechter. M**.; Harrison. L.H.; Ronchini, K.; Lederman, H.M. (1995) Immune dysfunction in HTLV-1 And HIV Coinfection More Severe Than in HIV Infection Alone. 35Th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA.
206. Harrison, L.H.; **Schechter, M**.; Vaz, B.; MD. JC. Mcarthur (1995). Myelopathy Among Brazilians Coinfected With Human T-Cell Lymphotropic Virus Type I and HIV. The VIIth International Conference on Human Retrovirology, Paris, França.
207. **Schechter. M**.; Harrison. L.H.; Ronchini, K.; T. C. Quinn; Lederman, H.M. (1995). Immune dysfunction in HTLV-1 and HIV coinfection: Results of a pilot study. The VIIth International Conference on Human Retrovirology, Paris, França.
208. Rodrigues, L.G.M.; Larouze, B.; and the French-Brazilian Research group on HTLV-1 (1995). HTLV I/II infection in Brazilian adult patients with neurologic conditions. The VIIth International Conference on Human Retrovirology, Paris, França.
209. Ramos, A.; Tanuri, A.; Janini, J.M.; Pinto, M.; **Schechter, M**.; Peralta, M.; Bandea, C.; Schochetman, G.; Rayfield, M.; Pieniazek, D. (1996). HIV-1 infections in Brazil: single, duals and recombinants. 96th ASM General Meeting, New Orleans.

210. Respass, R.; Butcher, A.; Wang, H.; Chaowanachan, T.; Young, N.; Shafer, N.; Mastro, T.; Biryahwaho, R.; Downing, R.; Tanuri, A.; **Schechter, M.**; Pascy, R.; Zekeng, L.; Kaptué, L.; Gurtler, L.; Ellenberg, C.; Fridland, M.; Rayfield, M.; Kwok, S. (1996). Detection of genetically diverse Human Immunodeficiency Virus Type I group M and O isolates by PCR. 3rd. Conference on Retrovirus and Opportunistic Infections, Washington, EUA.
211. Lyamya, E.F.; **Schechter, M.**; Echeveria de Perez, G.; Vercauteren, G. (1996). Multicentre Evaluation Of Alternative Methods For CD4 Lymphocyte Determination. XI International Conference On AIDS, Vancouver, Canadá.
212. Pinho, AMF; Lopes, GS; Lima, LAA; **Schechter, M.** (1996). Incidence Of Tuberculosis In A cohort of HIV-1 Infected Women In Rio de Janeiro, Brazil. XI International Conference On AIDS, Vancouver, Canadá.
213. Harrison, L.H.; Ferro, R.F.; Friedman, R.K.; Quinn, T.C.; Rodrigues, J.; **Schechter, M.** (1996). High Prevalence of STDs and Hig-Risk Behavior Among Men Who Have Sex With Men in an HIV Seroincidence Study In Brazil. XI International Conference On AIDS, Vancouver, Canadá.
214. Santos, E.M.; Lago, R.F.; Silva, S.B.; Costa, R.B.; **Schechter, M.**; Harrison, L.H. (1996). Recruitment for an HIV seroincidence study in Brazil: Alternative Approaches And Lessons Learned. XI International Conference On AIDS, Vancouver, Canadá.
215. Lago, R. F.; Harrison, L.H.; **Schechter, M.** (1996). Willingness Of Participants In An HIV Seroincidence Study In Rio De Janeiro, Brazil To Participate In Future Vaccine Trials. XI International Conference On AIDS, Vancouver, Canadá.
216. Pinto, M.E.; Tanuri, A.; **Schechter, M.** (1996). Frequency Of Subtypes Of HIV-1 in participants off A cohort study in Rio de Janeiro, Brazil, as suggested by endonuclease digestion patterns of the protease gene. 1996. XI International Conference On AIDS, Vancouver, Canadá.
217. Pinto, M.E.; Tanuri, A.; **Schechter, M.** (1996). Differences in the prevalence of HIV-1 subtypes in male and female participants of a cohort study in Rio de Janeiro, Brazil. XI International Conference On AIDS, Vancouver, Canadá.
218. Lopes, GS, Hofer, CB, Pinho, AMF, **Schechter, M.** (1996). Natural history of HIV-1 infection in women in Rio de Janeiro, Brazil. XI International Conference On AIDS, Vancouver, Canadá.
219. Lima, LAA; Neto PG; Pacheco, AGF; Faccio, MR; Neto, JS; Moulton, LH; **Schechter, M.** (1996). Impact of antiretroviral use on survival in a large brazilian seroprevalent cohort. XI International Conference on AIDS, Vancouver, Canadá.
220. Lewis-Ximenez, LL; Quinn, TC; Schatzmayer, H; Yoshida, CT; **Schechter, M.** (1996). Quantitative detection of Hepatitis C virus and Human Immunodeficiency Virus RNA in Brazilian Coinfected Patients. XI International Conference On AIDS, Vancouver, Canadá.
221. Harrison, L.H; Quinn, T.C.; **Schechter, M.**(1996). Human T-Cell Lymphotropic Virus Type I Does Not Increase HIV Viral Load *in Vivo*. 36th ICAAC, New Orleans, EUA.
222. Janini, L.M.' Tanuri, A.; **Schechter, M.**; Ramos, A.; Schochetman, G; Rayfield, M.; Pieniazek, D. (1997). Horizontal and Vertical Transmission of HIV-1 Dual Infections

- Caused by Viruses of Subtypes B and C. 4th Conference on Retroviruses and Opportunistic Infections, Washington, EUA.
223. **Schechter, M;** Moulton, LH; Harrison, LH. (1997). HIV viral load and CD4 lymphocyte counts in subjects coinfectd with HTLV-1 and HIV-1. 37th ICAAC, Toronto, Canada.
 224. Fortes, CQ; Chaves, IA; Nogueira, SA; **Schechter, M.**; Peixoto, CAM; Garbes Neto, P.. Endocarditis Due to *Corynebacterium diphtheriae*: Case Report. Fourth International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, La Marive, Yverdon-les-Bains, Switzerland, 1997.
 225. Pinto, ME; Tanuri, A; **Schechter, M.** Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1998.
 226. Barroso, PF; Harrison, LH; Souza, YC; Bonfim, AS; **Schechter, M;** Gupta, P. Impact of anti-retroviral therapy on HIV-1 seminal viral load. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1998.
 227. Friedman, R.K; Rodrigues, J; Fraga, L.F; Melo, M.F; Oliveira, L; **Schechter, M;** Harrison, H.L. (1998). Prevalence of markers for sexually transmitted diseases in a male population at high risk for HIV infection. 12th World AIDS Conference, Geneva
 228. **Schechter, M;** Pinho, A.M.F; Lima, L.A.L; Lopes, G.S. (1998). Risk factors for tuberculosis (TB) in a cohort of HIV-infected patients in Rio de Janeiro, Brazil. 12th World AIDS Conference, Geneva.
 229. Silva, S; Portella, J; Longo, P.H.P; Fernandes, N.N; Lago, R.F; Souza, M.B; **Schechter, M.** (1998). Unprotected oral sex among men who have sex with men (MSM). 12th World AIDS Conference, Geneva.
 230. Barroso, P.F; Harrison, H.L; Bressan, C.S; Melo, M.F; Gupta, P; **Schechter, M.** (1998). High correlation between plasma and seminal HIV-1 viral load in antiretroviral-naive Brazilian subjects. 12th World AIDS Conference, Geneva.
 231. Longo, P; Silva, S.N; **Schechter, M;** Harrison, L.H. (1998). Willingness to participate in a vaccine preparatory study in Rio de Janeiro, Brazil. 12th World AIDS Conference, Geneva.
 232. **Schechter, M;** Lopes, G; Pinho, A.M.F; Lima, L.A.A; Hofer, C.B; Harrison, L.H; Moulton, L.H. (1998). Gender and progression of HIV-associated immunodeficiency. 12th World AIDS Conference, Geneva.
 233. Barroso, P F; Gupta, P; **Schechter, M;** Melo, MF; Souza, Y; Harrison, LH (1999). Seminal HIV-1 Viral Load Is Reduced by Antiretroviral Therapy and Is Correlated with Plasma HIV-1 Viral Load. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1999.
 234. Harrison, LH; Do Lago, RF; Ismerio, T; **Schechter, M.** A High-Incidence Homosexual Male Cohort for Vaccine Trials in Brazil. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, USA, 1999.
 235. G.Santoro-Lopes, L.H. Harrison, M.D. Tavares, A Xexeo, **M. Schechter.** V3-Binding Serotypes and HIV Disease Progression in Brazil: Is B Different from B'?. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, USA. Setembro 26-29, 1999.

236. **Schechter, M**; R.F. Lago, R.I. Moreira, H.W. Sheppard, L.H. Harrison. The Sensitive/Less Sensitive HIV Testing Strategy to Identify a High-Risk Heterosexual Population for HIV Vaccine Trials in Brazil. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Califórnia, USA. Setembro 26-29, 1999.
237. L.H. Harrison, R.F. do Lago, R.I. Moreira, **M. Schechter**. Demand for Post-Sexual-Exposure Chemoprophylaxis for the Prevention of HIV Infection in Brazil. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Califórnia, USA. Setembro 26-29, 1999.
238. P.F. Barroso, **M. Schechter**, P. Gupta, M.F. Melo, M.Vieira, F.C. Murta, C. Bressan, S. Bomfim, L.H. Harrison. Seminal HIV-1 Shedding is Increased by the Presence of Genital Warts. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Califórnia, USA. Setembro 26-29, 1999.
239. P.F. Barroso, **M. Schechter**, P.Gupta, M.F. Melo, M. Vieira, F.C. Murta, Y. Souza, L.H. Harrison. Adherence to Antiretroviral Therapy (ART) is Associated with Seminal Viral Load (SVL) Suppression. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Califórnia, USA. Setembro 26-29, 1999.
240. C.B. Hofer, **M. Schechter**, R.I. Moreira, J.C. Struchiner, J. Rodrigues, R. Khalili, F. Melo, L.H. Harrison. The absence of a definition of Acute Retroviral Syndrome (ARS) in a Cohort of HIV-Seronegative Homosexual Men in Brazil. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Califórnia, USA. Setembro 26-29, 1999.
241. Barroso, PF; **Schechter, M**; Gupta, P; Murta, FC; Vieira, M; Melo, MF; Souza, Y; Harrison, LH. Rebound of Seminal HIV-1 Viral Load Associated with Sexually Transmitted Diseases (STDs) after Virologic Suppression by Antiretroviral Therapy. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 2000.
242. Barroso, PF; Harrison, LH; Gupta, P; Murta, FC; Souza, Y; Melo, MF; Vieira, M; **Schechter, M**. Predictors of Seminal Viral Load (SVL) Suppression in Subjects Starting Antiretroviral Therapy (ART). Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 2000.
243. **Schechter, M**; Lago, RF; Moreira, RI; Sheppard, HW; Guimarães, NC; Harrison, LH. Sensitive/Less-Sensitive HIV Testing Strategy to Identify a High-Risk Heterosexual Population in Brazil. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 2000.
244. Harrison, LH; Lago, RF; Moreira, RI; **Schechter, M**. Demand for Post-Sexual-Exposure Chemoprophylaxis for the Prevention of HIV Infection in Brazil. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 2000.
245. Grinsztejn, B; Bastos, FI; Veloso, VG; Russomano, F; Camargo, MJ; Silva, SM; Tarumano, E; Derrico, M; **Schechter, M**. Risk factors for HPV infection in a cohort of HIV-1 infected women with a high prevalence of co-infection by oncogenic HPV. XIII International AIDS Conference, Durban, África do Sul, 2000.
246. **Schechter, M**; Pinho, AMF; Lopes, GS; Tavares, MD. Tuberculosis and survival of HIV-infected patients in an area with a high prevalence of *M. tuberculosis infection*. XIII International AIDS Conference, Durban, África do Sul, 2000.

247. Fernandes, N; **Schechter, M**; Harrison, L; Lago, R. Homosexuality and willingness to participate in an HIV vaccine trial. XIII International AIDS Conference, Durban, África do Sul, 2000.
248. Friedman, RK; Rodrigues, J; Fernandes, MN; Moreira, IR; **Schechter, M**; Harrison, L. Acceptability of Post-Sexual-Exposure Chemoprophylaxis for the Prevention of HIV Infection in Brazil. XIII International AIDS Conference, Durban, África do Sul, 2000.
249. Souza, M; **Schechter, M**; Lago, R; Friedman, R; Harrison, L. Perception of risk and regular partnership among MSM in Rio de Janeiro, Brazil. HPV. XIII International AIDS Conference, Durban, África do Sul, 2000.
250. Santoro-Lopes, G; Pinho, AMF; **Schechter, M**. Reduced Risk of Tuberculosis (TB) among Patients with HIV Infection Treated with Highly Active Antiretroviral Therapy (HAART). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canadá, 2000.
251. Harrison, LH; Lago, RF; Moreira, RI; Mendelsohn, AB; **Schechter, M**. Post-Sexual-Exposure Chemoprophylaxis (PEP) for HIV: A Prospective Cohort Study of Behavioral impact. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 2001.
252. Vibhagool, A; Cahn, P; **Schechter, M**; Soto-Ramirez, L ; Montroni, M; Smail, F; Thomas, N. Abacavir/Combivir (ABC/COM) is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-week Open Label Study (CNA3013). The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
253. **Schechter, M**; Lago, R; Moreira, R; Mendelsohn, A; Harrison, L. Behavioral Impact of The Availability of Post Sexual Exposure Chemoprophylaxis (PEP) For HIV: A prospective Cohort Study. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
254. Pinto, M; **Schechter, M**; Struchiner, C; Russo, C. Evidence For Two Different Phylogenetic Distribution Patterns of GWGR and GPGR Variants of Subtype B HIV-1 Viruses in Brazil. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
255. Santoro-Lopes, G; Pinho, A; Harrison, L; **Schechter, M**. Reduced Risk of Tuberculose (TB) Among Patients With HIV Infection Treated with HAART in a Brazilian Cohort. The 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001.
256. **Schechter, M**; Lago, RF; Ismerio, R; Mendelsohn, AB; Harrison, LH. Acceptability, Behavioral Impact, and Possible Efficacy of Post-Sexual-Exposure Chemoprophylaxis (PEP) for HIV. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 2002.
257. Coplan, P; Nikas, A; Kallas, E; Pitisuttithum, P; **Schechter, M**; Puthavathana, P; Fu, TM; Dubey, S; Freed, D; Thaler, S; Mehrotra, D; Condra, J; Emini, E; Shiver, J. Reactivity of anti-HIV T-cell immune responses to different HIV-1 subtypes among HIV+ individuals from Brazil, Thailand and the US. XIV International AIDS Conference, Barcelona, Espanha, 2002.

258. Souza, M; Yoshida, C; Santos, G; **Schechter, M**; Valente, O. Community participation on HIV vaccine research in Brazil. XIV International AIDS Conference, Barcelona, Espanha, 2002.
259. Hofer, CB; **Schechter, M**; Harrison, LH. Effectiveness of antiretrovirals in patients who attend HIV clinics in Rio de Janeiro, Brazil. XIV International AIDS Conference, Barcelona, Espanha, 2002.
260. Grinsztejn, BG; Bastos, FI; Veloso, VG; Russomano, F; Morgado, M; Pilotto, JH; Friedman, RK; Taramaru, E; Derrico, M; **Schechter, M**. High HPV viral loads associated with advanced immunodeficiency and pre-invasive cervical lesions in HIV infected women in Rio de Janeiro, Brazil. XIV International AIDS Conference, Barcelona, Espanha, 2002.
261. Cook, RL; May, S; Harrison, LH; Ness, RB; Ismerio, R; **Schechter, M**. High prevalence of HIV and sexually transmitted infections among young women seeking HIV testing in Rio de Janeiro. XIV International AIDS Conference, Barcelona, Espanha, 2002.
262. Friedman, RK; Lourenço, MC; Veloso, VG; Grinsztejn, B; **Schechter, M**; Bastos, FI. HIV-infected marginalized and abused women from Rio de Janeiro, Brazil are heavily coinfecting with HPV but have low/moderate prevalences for other sexually transmitted infections. XIV International AIDS Conference, Barcelona, Espanha, 2002.
263. Varella, RB; Castro, MB; Ferreira, SB; **Schechter, M**; Tavares, MD. Frequent presence of polymorphisms in the protease and reverse transcriptase genes of viruses obtained from treatment-naive Brazilian patients. XIV International AIDS Conference, Barcelona, Espanha, 2002.
264. Barroso, PF; **Schechter, M**; Cerbino-Neto, J; Almeida, MHH; Littleton, M; Harrison, LH. Sexual activity after initiation of antiretroviral therapy in Brazil. XIV International AIDS Conference, Barcelona, Espanha, 2002.
265. Leth, FV; Phanuphak, P; Gazzard, B; Chan, P; Wood, R; Bloch, M; Katlama, C; **Schechter, M**; Murphy, R; Horban, A; Hall, D; Van der Valk, M; Lange, J; Reiss, P. Lipid Changes in a Randomized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together with Stavudine and Lamivudine (2NN Study). 10th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, 2003.
266. Lima, LA; **Schechter, M**; Jenkins, FJ; Moore, PS; Renwick, NM; Harrison, LH. Risk Factors for Kaposi's Sarcoma-associated Herpesvirus Infection among Homosexual Men at High Risk for HIV Infection in Brazil. 10th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, 2003.
267. Barroso, PF; **Schechter, M**; Cerbino-Neto, J; Almeida, MHH; Harrison, LH. Safer Sex After Initiation of Antiretroviral Therapy in a Public HIV Clinic in Brazil. 10th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, 2003.
268. Cook, R; May, S; Harrison, LH; Ismerio, R; Ness, R; **Schechter, M**. Risk Factors for HIV and STDs among Young Women Seeking HIV Testing in Rio de Janeiro. 10th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, 2003.
269. Tavares, MD; Varella, RB; Ferreira, SB; de Castro, MB; Malta, FC; **Schechter, M**. Large Scale use of Antiretroviral Drugs is not Associated with a High Prevalence of

- Genotypic Resistance Mutations in Treatment-Naive HIV-1 Infected Individuals in Rio de Janeiro, Brazil. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 2003.
270. Pinto, ME; **Schechter, M**; Struchiner, C; Miranda, AB; Russo, CAM. Is Natural Selection Involved in the Rapid Expansion of GWGR Subtype B Variant in Brazil? The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 2003.
 271. Barroso, PF; Harrison, LH; Melo, MF; Batista, S; Bastos, M; Faulhaber, J; Moreira, RI; Lago, RF; **Schechter, M**. Identification of a High-Risk Heterosexual Cohort for HIV Vaccine Efficacy Trials in Rio de Janeiro, Brazil. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 2003.
 272. May, SB; Cook, RL; Harrison, LH; Ness, RB; Ismério, R; Batista, S; **Schechter, M**. HIV and STI Interactions Among Young Women Seeking HIV Testing in Rio de Janeiro. The 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, 2003.
 273. Mast, TC; Gupta, S; Nikas, A; Kierstead, L; Kallas, EG; Mbewe, B; Pitisuttithum, P; **Schechter, M**; Vardas, E; Wolfe, N; Coplan, P; Aste-Amezaga, M; Shiver, J; Emini, EA; Straus, WL. International Epidemiology Human Pre-existing Anti-Adenovirus Type-5 (Ad5) Neutralizing Antibodies in Areas Representative of Potential HIV Vaccine Trial Sites. AIDS Vaccine 2003, New York, USA, 2003.
 274. Jack, N; **Schechter, M**; Pape, J; Sanchez, J; Jean, S; Lago, RF; Metch, B; Hansen, M; Harrison, L; Sanchez, J; Cleghorn, F; Wright, P; Bartholomew, C. Conduct of a Multi-site HIV Vaccine Trial (HIVNET026) in the Caribbean and South America. AIDS Vaccine 2003, New York, USA, 2003.
 275. Barroso, PF; Harrison, LH; Telles, S; Silva, SB; Nunes, EP; Almeida, MMT; Moreira, RI; Lago, RF; **Schechter, M**; Projeto Praça Onze. Recruitment of a High-risk Heterosexual Cohort for HIV Vaccine Efficacy Trials in Rio de Janeiro, Brazil. AIDS Vaccine 2003, New York, USA, 2003.
 276. Gupta, S; Nikas, A; Freed, D; Kallas, E; **Schechter, M**; Pitisuttithum, P; Vardas, E; Mbewe, B; Coplan, P; Mast, T; Kublin, J; Guess, H; Straus, W. Feasibility of Multisite International Epidemiologic Studies in Preparation of Large Scale HIV Vaccine Efficacy Trials. AIDS Vaccine 2003, New York, USA, 2003.
 277. **Schechter, M**. HIV post-sexual exposure prophylaxis. Int J Infect Dis, Suppl 1, 2004:S237. 11th International Congress on Infectious Diseases. Cancun, Mexico, 2004.
 278. Hofer, CB; **Schechter, M**; Harrison, LH. Morisky questions as a tool to evaluate adherence to antiretroviral therapy in public primary care clinics in Rio de Janeiro, Brazil. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 279. Souza, MB; **Schechter, M**; Yoshida, CB; Pedrosa, J; Santos, GRS; Weinstein, A. Involving community members in HIV vaccine research programs. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 280. Barroso, PF; Vergara, TRC; **Schechter, M**; Suarez-Kurtz, G; Estrela, RCE; Cerbino-Neto, J. Poor penetration of lopinavir in the genital tract of men receiving HAART in Brazil. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 281. Barroso, PF; Vettore, MV; **Schechter, M**; Melo, MF; Boechat, LJ. Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy XV International AIDS Conference, Bangkok,

- Tailândia, 2004.
282. Hofer, CB; **Schechter, M**; Harrison, LH. Factors associated with antiretroviral adherence in public clinics in Rio de Janeiro, Brazil. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 283. Mast, TC; Gupta, S; Nikas, A; Kierstead, L; Burke, D; Kallas, E; Novitsky, V; Mbewe, B; Pitisuttithum, P; **Schechter, M**; Vardas, E; Aste-Amezaga, M; Shiver, J; Emini, E; Straus, W. International epidemiology of human pre-existing anti-adenovirus Type-5 (Ad5) neutralizing antibodies in areas representative of potential HIV vaccine trial sites. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 284. Gupta, SB; Freed, DC; **Schechter, M**; Vardas, E; Kallas, E; Pitisuttithum, P; Mbewe, B; Kublin, J; Mpoudi-Ngole, E.; Novitsky, V; Nikas, A; Mast, TC; Coplan, P; Straus, W. Retention of subjects in a multi-site international epidemiology study In preparation of large scale HIV vaccine efficacy trials. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 285. Barroso, PF; Teles, S; Silva, SB; Melo, MF; Nunes, EP; Almeida, MMT; Fernandes, M; Lago, RF; Harrison, LH; **Schechter, M**. Recruitment of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil: Risk profile and willingness to participate in vaccine trials. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 286. Dabis F; Schneider M; **Schechter M**; Egger M. Characteristics of ART treatment programmes in low-income countries: the ART-LINC collaboration. XV International AIDS Conference, Bangkok, Tailândia, 2004.
 287. Barroso PF, Telles S, Silva SB, Nunes EP, Almeida MMT, Lago RF, Harrison LH, **Schechter M**. Recruitment and retention of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil: risk profile and willingness to participate in vaccine trials. AIDS Vaccine 2004 International Conference, Lausanne, Suíça, 2004.
 288. Dabis, F; **Schechter, M**; Egger, M. Response to Highly Active Retroviral Therapy in Low- and High-income Countries: Analysis of Clinical Databases from 4 Continents. 12th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, 2005.
 289. Tuboi, S; Sprinz, E; Harrison, LH; Albernaz, R; **Schechter, M**. Predictors of Virological Failure at 6 Months of Therapy in HIV-1-infected Patients Starting HAART in Porto Alegre, Brazil. 12th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, USA, 2005.
 290. May, S.B.; Barroso, P.F.; Santoro Lopes, G.; Nunes, E.; Barcaui, H.; Costa, M.; Almeida, M.; Faulhaber, J.; **Schechter, M**. Generic drugs, health delivery mode and effectiveness of HAART in Brazil. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
 291. Brinkhof M.; Braitstein, P.; Wood, R.; Kumarasamy, N.; Miotti, P.; Egger M.; Dabis, F; **Schechter, M**. Prognostic value of baseline total lymphocyte count (TLC) vs, absolute CD4 count in predicting survival among patients initiating HAART in low-income countries. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
 292. Charles M.; Boyle, B.; Mayer, K.H.; **Schechter, M**. Leveraging Western medical expertises to rapidly build healthcare systems for HIV/AIDS in developing countries. 3rd

- IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
293. Malave, M.; Charles, M.; Boyle, B.; Mayer, K.H.; Vun, M.C.; **Schechter, M.** The effectiveness of clinical mentoring as a method to improve HIV/AIDS clinical skills of healthcare professionals in Cambodia. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
 294. Braitstein, P.; **Schechter, M.**; Brinkhof, M.; Boulie, A.; Egger, M.; Dabis, F. How do different types of treatment regimens affect short-term response to Highly Active Antiretroviral Treatment (HAART) among adults initiating treatment in low-income countries? 3rd IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
 295. Braitstein, P.; Boulie, A.; Low, N.; Brinkhof, M.; **Schechter, M.**; Balestre, E.; Dabis, F.; Egger, M. Gender, access and response to potent antiretroviral in low-income countries: ART-LINC Collaboration. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
 296. Balestre, E.; Brinkhof, M.; Dabis, F.; **Schechter, M.**; Braitstein, P.; Egger, M.; Miotti, P.; Anglaret, X. Short-term incidence and risk factors for being lost to treatment in 16 antiretroviral treatment cohorts in low income countries. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
 297. Djomand, G.; Duerr, ^a; Struchiner, C.; Pacheco, G.; Barroso, P.; **Schechter, M.** Course of human immunodeficiency virus type 1 infection after seroconversion in a cohort of men who have sex with men (MSM) in Rio de Janeiro, Brazil. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24 a 27 de Julho de 2005, Rio de Janeiro, Brasil.
 298. Mast, T.; Kierstead, L.; Gupta, S.; Nikas, A.; Kallas, E.; Novitsky, V.; Mbewe, B.; Pitisuttithum, P.; **Schechter, M.**; Vardas, F.; Wolfe, N.; Aste-Amezaga, M.; Shiver, J.; Coplan, P.; Straus, W. Epidemiology of Human Pre-Existing Anti-Adenovirus type-6 and (AD6) and type-5 (AD5) Neutralizing Antibodies (NA) in Areas Representative of Potential HIV Vaccine Trials Sites. Vaccine, Montreal, Canadá, 2005.
 299. Cleghorn, F.; Jack, N.; Pape, J.; Sanchez, J.; **Schechter, M.**; Metch, B.; Hansen, M.; Cao, H; Tomaras, G.; Gurunathan, S.; Eastmen, D.; Wright, P. HIVNET 026: A Multi-Site International Trial of a HIV-1 Canarypox Vaccine (ALVAC-HIVVCP 1452) With or Without Boosting With MN RGP 120. Vaccine, Montreal, Canadá, 2005.
 300. Nunes, E.P.; Santini-Oliveira, M.; Almeida, M.; Pilotto, J.H; Ribeiro, J.E.; Faulhaber, J.C., **Schechter M.** Study on the feasibility of antiretroviral therapy with a single agent-Lopinavir/r- in patients treated with HAART and with viral load below 80 copies/ml-KalMo. 10th European AIDS Conference, Dublin, Ireland, 2005.
 301. Braitstein, P; Brinkhof, M; **Schechter, M.**; Kumarasamy, N; Nash, D; Boulle, A; Ekong, E; Dabis, F; Balestre, E; Egger, M. When Are Adults in Resource-constrained Settings Most Likely to Experience an HIV-associated Illness following HAART Initiation and What Is It Related To? 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, USA, 2006.
 302. **Schechter, M.**; Brinkhof, M; Egger, M; May, M; Nash, D; Sprinz, E; Dabis, F; Braitstein, P. Discordant Immunologic and Virologic Responses to ART among Previously Naive Adults Initiating HAART in Resource-constrained Settings. 13th

- Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, USA, 2006.
303. Brinkhof, M; Dabis, F; Braitstein, P; Schechter, M; Boulle, A; Balestre, E; Sterne, J; Egger, M. Censoring issues in observational HIV treatment cohorts: describing different approaches to censoring and their effects on estimates of mortality and losses to follow-up in a multinational cohort collaboration from resource-constrained settings. XVI International AIDS Conference, Toronto, Canada, 2006.
304. Hogg, RS; Braitstein, P; Weigle, R; Kumarasamy, N; Meade, T; Nash, D; Bangsberg, DR; Schechter, M; Sprinz, E; Sidle, JE; Pepper, L; Balestre, E; Brinkhof, M; Egger, M; Dabis, F. Life expectancy of HIV-infected men and women initiating HAART in resource-constrained settings: insights from the ART-LINC collaboration. XVI International AIDS Conference, Toronto, Canada, 2006.
305. Farley, S; Bomlitz, L; Charles, M; Kauffmann, R; Nelson, M; Mayer, KH; Schechter, M; Boyle, B. Clinical mentoring: tapping into the vast, mostly neglected, western resources to make a fast, sustainable, and effective contribution to putting AIDS patients on ART in developing countries. XVI International AIDS Conference, Toronto, Canada, 2006.
306. Périssé, ARS; Amorim, CMD; Silva, JRG; Schechter, M; Blattner, WA. Relationship of egocentric network characteristics and HIV transmission among MSM in Rio de Janeiro, Brazil. XVI International AIDS Conference, Toronto, Canada, 2006.
307. Souza, M; Santos, G; Pedrosa, J; Yoshida, C; Schechter, M. Building and retaining a group of potential volunteers for HIV vaccine trials in Rio de Janeiro, Brazil. XVI International AIDS Conference, Toronto, Canada, 2006.
308. Nunes, EP; Oliveira, MS; Almeida, MMTB; Pilotto, JH; Ribeiro, JE; Faulhaber, JC; Norton, M; Schechter, M; Zajdenverg, R. 48-week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/mL on HAART - the KalMo study. XVI International AIDS Conference, Toronto, Canada, 2006.
309. Steigbigel, R; Kumar, P; Eron, J; Schechter, M; Markowitz, M; Loufty, M; Zhao, J; Isaacs, R; Nguyen, B; Teppler, H. Results of BENCHMRK-2, a Phase III Study Evaluating the Efficacy and Safety of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-class Resistant Virus. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, USA, 2007.
310. Fonseca, AGP; Tuboi, S; Faulhaber, JC; Harrison, L; **Schechter, M**. Significant increases in cardiovascular diseases and diabetes as causes of death in HIV-infected individuals in the HAART era in Brazil: a population based analysis. 4th IAS Conference on HIV Pathogenesis and Treatment, Sydney, Australia, 2007.
311. Souza, MB; Barroso, PF; Lago, RG; Pedrosa J; Yoshida, CB; Faulhaber, JC; Costa, MD; **Schechter, M**. Barriers to recruit female commercial sex workers for HIV vaccine trials: The Rio de Janeiro Experience. AIDS Vaccine 2007, Seattle, EUA, 2007.
312. Almeida, MBT; Grangeiro, JR; Campos A; Batista, SM; Tuboi, SH; Lago, RF; Zajdenverg, R; Melo, MF; **Schechter, M**. Risk Factors for Recent HIV-1 Infection at an HIV Testing Site in Rio de Janeiro, Brazil: A Case-Control Study. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, EUA, 2007.
313. Nunes, EP; Oliveira, MS; Almeida, MMTB; Pilotto, JH; Ribeiro, JE; Faulhaber, JC; Norton, M; Zajdenverg, R; **Schechter, M**. 96-week efficacy and safety results of

simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/mL on HAART - the KalMo study. 11th European AIDS Conference, Madrid, Spain, 2007.

314. Merçon, M; Tuboi,SH; Grangeiro,JR;Ferro do Lago R; Zajdenverg,R; Batista,SM; , Campos, A; Melo, MF; Barroso, PF; **Schechter, M.** Identification of Risk Factors for Recent HIV-1 Infection in a HIV Testing Site in Rio de Janeiro, Brazil. 11th European AIDS Conference, Madrid, Spain, 2007.
315. Campbell, T; Mills, A; Morlat, P; **Schechter, M;** De Smedt, G; Peeters, M; Tomaka, F; Woodfall, B. TMC125 Safety and Tolerability in Treatment-Experienced Hepatitis B or C Co-infected Patients in DUET-1 and DUET-2. *Global Antiviral Journal* 2007, 3 (Suppl. 2), page 103 (abstract 96).
316. Steigbigel, R; Kumar, P; Eron, J; **Schechter, M;** Markowitz, M; Loutfy, M; Zhao, J; Isaacs, R; Nguyen, BY; Tepler, H. 48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir in Patients Failing ART with Triple-class Resistant HIV. 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2008.
317. May, M; Boulle, A; Messou, E; Tweya, H; Myer, L; Wood, R; Sterne, J; **Schechter, M;** Egger, M.. Mortality of HIV-1-infected Patients Starting ART in Sub-Saharan Africa: The IeDEA Prognostic Model. 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2008.
318. Tuboi, S; Pacheco, A; Braitstein, P; May, M; Stone, R; Sprinz, E; Nash, D; Wood, R; Harrison, L; **Schechter, M.** Effect of Early Immunovirologic Discordant Responses on Mortality in Naïve HIV-1-infected Adults Initiating Treatment in Resource-constrained Countries. 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 2008.
319. Tuboi, S; Shepherd, B; Cesar, C; Krolewiecki, A; Cahn, P; Wolff, M; Pape, J; Gotuzzo, E; Bacon, M; McGowan, C; Masys, D; **Schechter, M.** Mortality during the first year of potent antiretroviral therapy in HIV-1-Infected patients from 5 treatment centers in the Caribbean and Latin America. XVII International AIDS Conference, México, 2008.
320. Cesar, C; Shepherd, B; **Schechter, M;** Wolff, M; Pape, J; Gotuzzo, E; Bacon, M; McGowan, C; Masys, D; Cahn, P. Reasons for change of first potent antiretroviral therapy in HIV-1-Infected patients in 5 sites throughout the Caribbean and Latin America. XVII International AIDS Conference, México, 2008.
321. Katlama, C; Campbell, T; **Schechter, M;** Peeters, M; Bicer, C; Sinha, R; Leopold, L; De Smedt, G. Incidence and severity of nervous system and psychiatric events are similar with etravirine (TMC125, ETR) versus placebo: pooled 48-week data from the phase III DUET studies. XVII International AIDS Conference, México, 2008.
322. Pacheco, A.G; Saraceni, V; Tuboi, S; Moulton, L. H; Golub, J.E; Durovni, B; Faulhaber, J.C; King, B; Cavalcante, S; Harrison, L. H; Chaisson, R. E; **Schechter, M.** Underreporting deaths among HIV-Infected/AIDS patients in Rio de Janeiro, Brazil. XVII International AIDS Conference, México, 2008.

PARTICIPAÇÕES EM CONGRESSOS NACIONAIS

323. Senna, M.; Murta, A.C.; **Schechter, M.;** Miles, M.A.; Peralta, J.M.; Mendonca-Previato, L.; Scharfstein, J. (1985). GP25 antigen of *Trypanosoma cruzi*: Identification

- of a 60 Kd precursor with monoclonal antibodies. X Congresso Brasileiro de Imunologia, Guarujá, Brasil.
324. Leme, V.M.C.; Murta, A.C.M.; **Schechter, M.**; Miles, M.A.; Mendonca-Previato, L.; Scharfstein, J. (1985). Characterization of a cross-reactive antigen of *T. cruzi* defined with Sleeping Sickness sera. X Congresso Brasileiro de Imunologia, Guarujá, Brasil.
 325. Murta, A.C.M.; Leme, V.M.C.; Mendonca-Previato, L.; **Schechter, M.**; Miles, M.A.; Scharfstein, J. (1985). Involvement of carbohydrate structures in the antigenicity of *T. cruzi* glycoproteins GP25 and GP 50/55. XIV Reuniao Anual da Sociedade Brasileira de Bioquímica, Caxambu, Brasil.
 326. Leme, V.M.C.; Vieira, E.; **Schechter, M.**; Miles, M.A.; Van Meirvene, N.; Mendonca-Previato, L.; Scharfstein, J. (1985). Identification of *T. cruzi* glycoprotein GP 50/55 as a cross-reactive antigen of Trypanosomatids. XII Reuniao Anual de Pesquisa Basica em Doença de Chagas, Caxambu, Brasil.
 327. **Schechter, M.**; Nogueira, N.; Cross, G.A.M. (1987). Descriptive analysis of *Trypanosoma cruzi* surface antigen profile: variations induced by different methodologies. XIV Reuniao Anual de Pesquisa Basica em Doença de Chagas, Caxambu, Brasil.
 328. Tendrich, M.; Feijo, P.; Monteiro, C.B.; **Schechter, M.**; Man, M. (1989). Associação de Diabetes Insipidus central e AIDS. V Simposio Internacional de Neuroendocrinologia, Sao Paulo, Brasil.
 329. Manela-Azulay, M.; Caneschi, J.R.T.; Cavalcanti, M.; Ramos-Filho, C.F.; Perez, M.A.; **Schechter, M.**; Pereira Jr., A.C. (1990). Achados dermatologicos nos pacientes com doença relacionada ao HIV em estagios Avancados no Brasil. XIII Reuniao Anual dos Dermatologos Latino-Americanos do Cone Sul, Rio de Janeiro, Brasil.
 330. Rodrigues, K.M.; Castineiras, T.M.P.P.; Santos, M.S.; Pereira, M.T.; Papi A.; D'avila, C.; Duarte, F.; **Schechter, M.**; Novis, S. (1990). AIDS e Miopatia. 14^o congresso Brasileiro de Neurologia, Rio de Janeiro, Brasil.
 331. Sohler, M.P.; Correa, R.B.; Perez, M.A.; **Schechter, M.**; Ramos-Filho, C.F.; Novis, S.A.P. (1990). Critérios para o diagnostico de neurotoxoplasmose: Serão adequados? Revisão de 80 casos. 14^o congresso Brasileiro de Neurologia, Rio de Janeiro, Brasil.
 332. Sohler, M.P.; Correa, R.B.; Perez, M.A.; **Schechter, M.**; Ramos-Filho, C.F.; Novis, S.A.P. (1990). Complicações Neurológicas da SIDA/AIDS Experiencia do HUCFF-UFRJ. 14^o congresso Brasileiro de Neurologia, Rio de Janeiro, Brasil.
 333. May, S.B.; Ramos-Filho, C.F.; Castilho, E.A.; Landman, C.; Pinto, M.E.; **Schechter, M.** (1991). Soroprevalencia de HIV-1 nas pueperas do Rio de Janeiro: resultados preliminares. VI Congresso Brasileiro de Infectologia, Salvador, Bahia, Brasil.
 334. Cruz, M. W.; Sohler, M. P.; Correa, R. B.; Cavalcanti, M.; **Schechter, M.**; Novis, S. (1991). Alterações eletroneuromiográficas associadas a infecção pelo HTLV-1 numa família brasileira. XII Congresso Brasileiro de Eletroencefalografia e Neurofisiologia Clínica, Gramado, Rio Grande do Sul.
 335. Cruz, M. W.; Sohler, M. P.; Correa, R. B.; Cavalcanti, M.; **Schechter, M.**; Novis, S. (1991). Estudo eletroneuromiográfico em 10 pacientes com mielopatia associada ao HTLV-1. XII Congresso Brasileiro de Eletroencefalografia e Neurofisiologia Clínica, Gramado, Rio Grande do Sul.

336. Andrade, V.L.; Avelleira, J.C.; Marques, A.; Vxianna, F.R.; **Schechter, M.** (1991). Lepra como causa de resultados falso-positivos em testes sorologicos para deteccao de anticorpos anti-HIV. Congresso Brasileiro de Dermatologia, Belo-Horizonte, Minas Gerais.
337. Cavalcanti, M.; **Schechter, M.**; Sohler, M.; Leite, D.M.; Ferreira-Junior, O.C. (1991). Transmissao vertical e horizontal de HTLV-1 em 4 geracoes de uma familia. VI Reuniao Anual da FESBE, Caxambu, Minas Gerais.
338. **Schechter, M.**; Leite, DM; Zajdenverg, R; Machado,LL; Ramos, CF; Perez, MA. (1992). Predicao de contagem de CD4 nos individuos infectados pelo HIV. III Congresso de Infectologia dos paises de lingua portuguesa, I Congresso de Infectologia do Mercosul, Sao Paulo, SP.
339. Edelenyi, MP; Carvalho, AP; Artemenko, S; Ferreira Jr, OC; Nogueira, C; **Schechter, M.** (1992). Prevalencia de anticorpos para o virus da Hepatite C em populacoes de baixo e alto risco para doencas de transmissao sexual. III Congresso de Infectologia dos paises de lingua portuguesa, I Congresso de Infectologia do Mercosul, Sao Paulo, SP.
340. **Schechter, M.**; Trade, GCS; Santa-Rosa, AAP (1992). Impacto da infeccao pelo HTLV-1 em pacientes infectados pelo HIV-1. III Congresso de Infectologia dos paises de lingua portuguesa, I Congresso de Infectologia do Mercosul, Sao Paulo, SP.
341. Lacerda, MCR; Cardoso, SW; Perez, MA; **Schechter, M** (1992). Atendimento publico X Atendimento privado: Impacto na sobrevida de pacientes com AIDS. III Congresso de Infectologia dos paises de lingua portuguesa, I Congresso de Infectologia do Mercosul, Sao Paulo, SP.
342. Carvalho, ACC; Kritski, AL; Bertoche, GLM; Costa, PA; Pessoa, CLC; Orfalis, CS; Lucharewsky, BR; Werneck, EB; **Schechter, M.**; Andrade, GN (1992). Tuberculose infeccao e doenca entre comunicantes de paciente com tuberculose pulmonar e infeccao pelo HIV. Estudo prospectivo: Resultados preliminares. XXVI Congresso Brasileiro de Pneumologia e Tisiologia, Jornal de Pneumologia 1992, 18 (2):109.
343. Correa, RB; Sohler, MP; Vaz, BP; **Schechter, M.**; Novis, SAP (1992). Mielopatia associada a infeccao por HTLV-1: Experiencia do HUCFF-UFRJ. XV Congresso Brasileiro de Neurologia, Porto Alegre, RS.
344. Hofer, CB; Pinto, ME; Zajdenverg, R; **Schechter, M** (1993). A frequencia de antigenemia e sua correlacao com criterios evolutivos na infeccao pelo HIV no Brasil. XXIX Congresso da Sociedade Brasileira de Medicina Tropical, Fortaleza, Ceara.
345. Oliveira, RHS; Collareda, NL; Frota, AC, **Schechter, M.** (1993). Aleitamento e transmissao vertical do HIV-1. XXVIII Congresso Brasileiro de Pediatria, Salvador, Bahia.
346. **Schechter, M.**; Pinto, ME; Hofer, CB; Zajdenverg, R. (1993). Correlates of p24 antigenemia in HIV-1 infected Brazilian individuals. XVIII Congresso Brasileiro de Imunologia.
347. Pinto, ME; Carvalho, AP; Nogueira, C; Ferreira-J, O; **Schechter M.** (1993). Prevalence of antibodies to Hepatitis C virus in populations at low and high risk for sexually transmitted diseases in Rio de Janeiro. XVIII Congresso Brasileiro de Imunologia.

348. Dines, I; **Schechter, M**; Silva, AT; Persechini, PM. (1993). Natural Killer cell function and number in HIV-1 positive patients: CD16/56⁺ with CD3⁻ or CD3⁺ phenotype. XVIII Congresso Brasileiro de Imunologia.
349. Dines, I; **Schechter, M**; Silva, AT; Persechini, PM. (1993) Clinical correlates of NK cell number and activity in HIV positive patients. XVIII Congresso Brasileiro de Imunologia.
350. Cruz, M. W.; Sohler, M. P.; Correa, R. B.; Cavalcanti, M.; **Schechter, M**.; Novis, S. (1993). Eletro-neuromiografia e potenciais evocados somato-sensitivos em pacientes com mielopatia associada ao HTLV-1. IX Jornada Brasileira de doenças neuromusculares, São José do Rio Preto, São Paulo.
351. Collareda, NL; Frota, AC; Silva-Oliveira, RH; **Schechter, M**. (1993). Aleitamento Materno e transmissão vertical do HIV-1. XXVIII Congresso Brasileiro de Pediatria, Salvador, Bahia.
352. Nucci, M; **Schechter, M**; Spector, N; Pulcheri, W; Caiuby, MJ; Morais, JC; Maceira J; Carvalho, DM; Oliveira, HP (1993). Fatores de risco para infecções fúngicas disseminadas em pacientes neutropênicos: Estudo caso-controle. XIV Congresso Nacional do Colégio Brasileiro de Hematologia, VI Simpósio Brasileiro de Transplante de Medula Óssea, III Encontro Nacional de Enfermagem em transplante de medula óssea e hematologia, III Simpósio Latino Americano de Hemafereses, Curitiba, Paraná.
353. Torres, S; **Schechter, M**; Basilio, CA; Cortezzi, W (1995). Infecção pelo vírus Herpes Simples resistente ao aciclovir. III Congresso e XXI Jornada Brasileira de Estomatologia, Gramado, Rio Grande do Sul.
354. Pinto, ME; Goes F^o, Ramos CAB; Janini, LM; Pieniazek, D; Rayfield, MA; **Schechter, M**; Tanuri, A. (1995). Genetic variation in protease gene of HIV-1 in Rio de Janeiro. XXIV reunião anual da Sociedade Brasileira de Bioquímica.
355. **Schechter, M**; Harrison L.H.; Ronchini, K; Lederman, H.M. (1995). In Vivo T-Cell Dysfunction in Coinfection With Human T-Cell Lymphotropic Virus Type I (HTLV-I) and HIV. I Simpósio Brasileiro de Pesquisa Básica em HIV/AIDS, Angra dos Reis, Rio de Janeiro.
356. Filho, T.G.J.; Pinto, M.E.; Costa J.L; Brigadeiro M.R.; Vicente, C.A.; Pieniazek, D.; Rayfield A.M.; **Schechter, M**.; Tanuri, A.(1995). Characterization of HIV-I Dual Infection in Patients of Rio de Janeiro. I Simpósio Brasileiro de Pesquisa Básica em HIV/AIDS, Angra dos Reis, Rio de Janeiro.
357. Pinto M.E.; Tanuri, A.; **Schechter, M**. (1995). Frequency of Subtypes of HIV-1 in Participants of a Cohort Study in Rio de Janeiro as Suggested by Endonuclease Digestion Patterns of The Protease Gene. I Simpósio Brasileiro de Pesquisa Básica em HIV/AIDS, Angra dos Reis, Rio de Janeiro.
358. Pinto M.E.; Tanuri, A.; **Schechter, M**. (1995). Differences in The Prevalence of HIV-1 Subtypes in Male and Female Participants of a Cohort Study in Rio de Janeiro. I Simpósio Brasileiro de Pesquisa Básica em HIV/AIDS, Angra dos Reis, Rio de Janeiro.
359. Vaz, B.; **Schechter, M**.; Harrison, L.H.; McArthur, J.C. (1995). Myelopathy Among Brazilians Coinfected With Human T-Cell Lymphotropic Virus Type I And HIV. I Simpósio Brasileiro de Pesquisa Básica em HIV/AIDS, Angra dos Reis, Rio de Janeiro.

360. **Schechter, M.**; Quinn, TC; Harrison, LH. (1996). Coinfecção por HTLV-1 Não Aumenta a Carga Viral de HIV *In Vivo*.. IX Congresso Brasileiro de Infectologia. Recife, PE.
361. Pinho, AMF, Lopes, GS, Lima LAA, **Schechter, M.**(1996) Incidência de Tuberculose (TB) Em Uma Coorte de Mulheres No Rio de Janeiro. IX Congresso Brasileiro de Infectologia. Recife,PE.
362. Pinho, ME, Tanuri, A. **Schechter, M.**(1996). Diferenças Na Prevalência de Subtipos de HIV-1 Entre Homens e Mulheres Participantes de Um Estudo de Coorte No Rio de Janeiro. IX Congresso Brasileiro de Infectologia. Recife,PE.
363. Lima, LAA, Netto, PG, Pacheco, AGF, Faccio, MR, Neto, JC, Moulton, L, **Schechter, M.**(1996). Impacto do Uso de Anti-Retroviral na Sobrevida em Uma Coorte de Pacientes Infectados Pelo HIV. IX Congresso Brasileiro de Infectologia. Recife,PE.
364. Lopes, GS, Hofer, CB, Pinho, AMF, Lima, LAA, **Schechter, M.** (1996). Infecção Por HIV em Mulheres: Análise Descritiva de Uma Coorte no Rio de Janeiro. IX Congresso Brasileiro de Infectologia. Recife,PE.
365. VA, BP, Harrison, LH, Taveira, DM, Quinn, TC, Souda, SH, McArthur, JC, **Schechter, M.**(1996). Manifestações Neurológicas Associadas À Coinfecção HIV/HTLV-1. IX Congresso Brasileiro de Infectologia. Recife,PE.
366. Khalili, R, Rodrigues, J, Melo, MF, Harrison, LH, **Schechter, M.**(1996). Prevalência de Marcadores de Doenças Sexualmente Transmissíveis em Uma População Masculina de Alto Risco Para a Infecção Pelo HIV. IX Congresso Brasileiro de Infectologia. Recife,PE.
367. Lewis-Ximenez, LL, Quinn, TC, Schatzmayer, H. Yoshida, CT, **Schechter, M.**(1996). Quantificação da Carga Viral de HCV e de HIV em Pacientes Coinfectados por Ambos os Vírus. IX Congresso Brasileiro de Infectologia. Recife,PE.
368. Melo, MF, Godomiczer, A., Schmaltz, CAT, Harrison, LH, **Schechter, M.** (1996). Validação de Um Teste Rápido Para o Diagnóstico Sorológico em uma População Masculina de Alto Risco para a Infecção Pelo HIV. IX Congresso Brasileiro de Infectologia. Recife,PE.
369. Lopes, GS; Pinho, AMF; Lima, LAA; Hofer, CB; Harrison, LH; Moulton, L; **Schechter, M.** Sobrevida após SIDA: Estudo Comparativo entre sexos. VII Congresso Panamericano X Congresso Brasileiro de Infectologia, 18 a 23 de Maio, Salvador, Bahia, 1997.
370. Pinho, AMF; Lopes, GS; Lima, LAA; **Schechter, M.** Incidência de tuberculose em uma coorte de pacientes com infecção pelo vírus da imunodeficiência humana. VII Congresso Panamericano X Congresso Brasileiro de Infectologia, 18 a 23 de Maio, Salvador, Bahia, 1997.
371. Dines, I; Harrison, LH; Lira, MCS; Barroso, PF; **Schechter, M.** Ausência de associação entre o sistema de estágios da OMS e carga viral do vírus da imunodeficiência humana (HIV). VII Congresso Panamericano X Congresso Brasileiro de Infectologia, 18 a 23 de Maio, Salvador, Bahia, 1997.
372. Pinto, ME; **Schechter, M.**; Tanuri, A. Análise do polimorfismo do gene da protease do HIV-1 em amostras do Rio de Janeiro. II Simpósio Brasileiro de Pesquisa Básica em HIV/AIDS, 07 a 11 de Setembro de 1997, Angra dos Reis, RJ.

373. Melo, MF; Rosa-Santos, OL; Schmaltz, CAE; Godomicz, A; Marinho, FM; Barros, ACM; Cunha, JMT; Silva, AG; Pinto, ME; **Schechter, M.** Soroprevalência do *Herpes simplex* virus em doadores de sangue e em uma população masculina de alto risco para a infecção pelo HIV. II Simpósio Brasileiro de Pesquisa Básica em HIV/AIDS, 07 a 11 de Setembro de 1997, Angra dos Reis, RJ.
374. Lopes, G.S.; **Schechter, M.**; Santos, ACE; Xexeo, Tavares, M.D.; Harrison, L. Sorotipo da Infecção pelo HIV no Rio de Janeiro. XI Congresso Brasileiro de Infectologia, 01 a 04 de Agosto de 1999, Palácio das Convenções, Anhembi, São Paulo, Brasil.
375. Lopes, G.S.; Lederman, H.M.; **Schechter, M.**; Ronchini, K.; Harrison, L.; Pereira, E.M.M. Estudo da Resposta Imune na Coinfecção HTLV-I/HIV. XI Congresso Brasileiro de Infectologia, 01 a 04 de Agosto de 1999, Palácio das Convenções, Anhembi, São Paulo, Brasil.
376. Pinto, M.E.; **Schechter, M.**; Struchiner, C.J.; Russo, C.A.M. Evidência Molecular de Padrões Distintos de Distribuição para os Variantes GWGR e GPGR do Subtipo B de HIV-1 Encontrados no Brasil. V Congresso Brasileiro de Epidemiologia - Epi 2002, 23 a 27 de Março de 2002, Curitiba, Paraná, Brasil.

ORIENTAÇÃO DE TESES

377. Luiz Antonio Alves de Lima - Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1992, intitulada "Validação do Sistema de estágios da Organização Mundial da Saúde para infecção pelo HIV em adolescentes e adultos".
378. Marta Cavalcanti - Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1992, intitulada "Estudo da ocorrência de infecção pelo HTLV 1 em quatro gerações de uma família brasileira e revisão da literatura".
379. Amâncio Paulino de Carvalho - Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1992, intitulada "Transmissão sexual do Vírus da Hepatite C".
380. Ana Maria Felix de Pinho - Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1992, intitulada "Bacteriúria em pacientes infectados pelo HIV".
381. Marcio Luiz Moore Nucci - Tese de Doutorado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1993, intitulada "Fatores de risco para infecções fúngicas disseminadas em pacientes neutropênicos - Estudo caso-controle".
382. Beatriz Pereira Vaz - Tese de Mestrado, Departamento de Clínica Médica, Faculdade de Medicina, UFRJ, 1996, intitulada "Mielopatia associada à co-infecção pelo HTLV-1 e HIV".
383. Monica Edelenyi Pinto - Tese de Mestrado, Instituto de Biofísica Carlos Chagas Filho, UFRJ, 1997, Intitulada "Análise do polimorfismo de restrição do gen da protease do HIV em amostras do Rio de Janeiro".
384. Rosângela Maria de Castro Cunha - Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1997, intitulada "Soroepidemiologia da Rubéola em mulheres puérperas atendidas pelo Sistema Único de Saúde em Juiz de Fora, Minas Gerais".

385. Guilherme Santoro Lopes - Tese de Doutorado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1998, intitulada “Prognóstico da infecção pelo HIV na cidade do Rio de Janeiro. Estudo comparativo entre os sexos”.
386. Henrique Sérgio de Moraes Coelho, Tese de Doutorado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1998, intitulada “Detecção de anticorpos contra o vírus da Hepatite C na prevenção da infecção pós-transfusional pelo vírus da Hepatite C.
387. Cristina Barroso Hofer, Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1998, intitulada “Descrição da síndrome retroviral aguda em homens que relatam fazer sexo com homens, no Rio de Janeiro.”
388. Marisa Dias Tavares, Tese de Doutorado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 1999, intitulada “Estudo de uma infecção lentiviral por SIVagm em duas espécies de macacos africanos”.
389. Marcia Cristina Rachid de Lacerda, Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 2000, intitulada “Efetividade da Terapia com dois análogos de Nucleosídeos Inibidores da Transcriptase Reversa em Pacientes com Infecção pelo HIV, virgens de Tratamento”.
390. Ana Maria Félix de Pinho, Tese de Doutorado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 2000, intitulada “Fatores de Risco Impacto na sobrevida em uma Coorte de Pacientes com infecção pelo HIV.”
391. Karla Regina Oliveira de Moura Ronchini, Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 2000, intitulada “Impacto Imunológico da coinfeção pelo HIV e HTLV-1: resultados de um estudo piloto”.
392. Beatriz Gilda Jegerhorn Grinsztejn, Tese de Doutorado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 2001, intitulada “Prevalência de infecções sexualmente transmissíveis e estudo dos fatores de risco para infecção pelo HPV numa coorte de mulheres infectadas pelo HIV no Rio de Janeiro”.
393. Marcelo Vianna Vettore, Tese de Mestrado, Departamento de Medicina Preventiva, Faculdade de Medicina, UFRJ, 2003, intitulada “Correlação entre a carga viral do HIV-1 no sangue e no trato genital feminino”.
394. Leonardo Kalab Leiroz, Tese de Mestrado, Departamento de Medicina Preventiva, UFRJ, 2008, intitulada “Susceptibilidade Antimicrobiana e Distribuição de Sorotipos de Amostras de *Streptococcus pneumoniae* Causadoras de Doença Invasiva no Município do Rio de Janeiro”.

PARTICIPAÇÕES EM BANCAS DE TESE

395. Instituto de Microbiologia da UFRJ, Banca Examinadora da Defesa de Tese de Mestrado do Dr. Fernando Jorge Bornay Llinares, 1991.
396. Disciplina de Clínica Médica, Faculdade de Medicina, UFRJ, Banca Examinadora da Defesa de Tese de Mestrado do Dr. Jose Rodolpho Rocco, 1991.
397. Instituto de Fisiologia e Pneumologia, UFRJ, Banca examinadora da Defesa de Tese de Mestrado do Dr. Afranio Lineu Kritski, 1992.
398. Disciplina de Dermatologia, Faculdade de Medicina, UFRJ, Banca examinadora da defesa de Tese de Mestrado da Prof. Monica Manela-Azulay, 1992.

399. Disciplina de Doenças Infecciosas e Parasitárias, Escola Paulista de Medicina, Banca examinadora da defesa de Tese de Doutorado do Prof. Ricardo Sobhie Diaz, 1993.
400. Instituto de Biofísica da UFRJ. Banca examinadora da defesa de tese de Mestrado do aluno Renato Augusto Damatta, 1993.
401. Escola Nacional de Saúde Pública da Fiocruz. Banca examinadora da defesa de tese de Mestrado da aluna Mônica Edelenyi Pinto, 2003.

PARTICIPAÇÕES EM BANCAS DE TESE E COMITÊS DE PROMOÇÃO EM UNIVERSIDADES NO EXTERIOR

402. Johns Hopkins University School of Public Health, Baltimore, Maryland, EUA. Comitê de Promoção para Pesquisador Associado do Dr. Chris Beyrer, 1999.
403. Johns Hopkins University School of Medicine, Baltimore, Maryland, EUA. Comitê de Promoção para Professor Titular de Obstetrícia e Ginecologia da Dra. Jean Anderson, 2005.
404. Johns Hopkins University School of Medicine, Baltimore, Maryland, EUA. Comitê de Promoção para Professor Titular de Medicina e Epidemiologia do Dr. Joel Gallant, 2006.
405. School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia. Banca examinadora da defesa de tese de Doutorado do aluno Jialun Zhou, 2007.
406. Vanderbilt School of Medicine, Nashville, Tennessee, EUA. Comitê de Promoção para Professor Titular de Medicina do Dr. Timothy Sterling.